<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
         xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         dtd-version="1.1"
         xml:lang="sl"
         article-type="other">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="nlm-ta">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="doi">Zdrav Vestn</journal-id>
         <journal-title-group>
            <journal-title>Zdravniški vestnik</journal-title>
            <trans-title-group xml:lang="en">
               <trans-title>Slovenian Medical Journal</trans-title>
            </trans-title-group>
            <abbrev-journal-title>Zdrav Vestn</abbrev-journal-title>
         </journal-title-group>
         <issn publication-format="ppub" pub-type="ppub">1318-0347</issn>
         <issn publication-format="epub" pub-type="epub">1581-0224</issn>
         <issn-l>0350-0063</issn-l>
         <publisher>
            <publisher-name xml:lang="sl">Slovensko zdravniško društvo</publisher-name>
            <publisher-name xml:lang="en">Slovenian Medical Association</publisher-name>
            <publisher-loc xml:lang="sl">Ljubljana, Slovenia</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.6016/ZdravVestn.2523</article-id>
         <article-id pub-id-type="publisher-id">2523</article-id>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Cardiovascular system</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="discipline" xml:lang="sl">
               <subject>Medicina/Zdravstvo</subject>
               <subj-group>
                  <subject>Srce in ožilje</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Original scientific article</subject>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="sl">
               <subject>Izvirni znanstveni članek</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="sl">
               <subject>Srce in ožilje</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="sl">Analiza bolnikov z anemijo zaradi pomanjkanja železa v hematološki ambulanti</article-title>
            <trans-title-group>
               <trans-title xml:lang="en">Survey of patients with iron deficiency anemia in haematology outpatient clinic</trans-title>
            </trans-title-group>
            <alt-title alt-title-type="running-head" xml:lang="sl">Analiza bolnikov z anemijo zaradi pomanjkanja železa v hematološki ambulanti</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Cvejić Vidali</surname>
                  <given-names>Gaja</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
               <xref ref-type="corresp" rid="corr"/>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Zver</surname>
                  <given-names>Samo</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
         </contrib-group>
         <aff-alternatives id="aff1">
            <aff xml:lang="sl">
               <label>1</label>
               <institution>Klinični oddelek za hematologijo, Interna klinika, Univerzitetni klinični center Ljubljana, Ljubljana</institution>
            </aff>
            <aff xml:lang="en">
               <label>1</label>
               <institution>Department of Haematology, Division of Internal Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <author-notes>
            <fn fn-type="conflict" xml:lang="en">
               <p>The authors have declared that no competing interests exist.</p>
            </fn>
            <fn fn-type="conflict" xml:lang="sl">
               <p>Avtorji so izjavili, da ne obstajajo nobeni konkurenčni interesi.</p>
            </fn>
            <corresp id="corr">Gaja Cvejić Vidali, e-mail: <email xlink:type="simple">gaja.vidali@gmail.com</email>
            </corresp>
         </author-notes>
         <pub-date pub-type="ppub">
            <month>6</month>
            <year>2018</year>
         </pub-date>
         <pub-date pub-type="epub">
            <month>6</month>
            <year>2018</year>
         </pub-date>
         <volume>87</volume>
         <issue>5–6</issue>
         <fpage>223</fpage>
         <lpage>36</lpage>
         <history>
            <date date-type="received">
               <day>28</day>
               <month>3</month>
               <year>2017</year>
            </date>
            <date date-type="accepted">
               <day>2</day>
               <month>3</month>
               <year>2018</year>
            </date>
         </history>
         <permissions>
            <copyright-statement xml:lang="en">Copyright © 2018, Slovenian Medical Association (SZD)</copyright-statement>
            <copyright-statement xml:lang="sl">© 2018, Slovensko zdravniško društvo (SZD)</copyright-statement>
            <copyright-year>2018</copyright-year>
            <copyright-holder xml:lang="en">Slovenian Medical Association (SZD)</copyright-holder>
            <copyright-holder xml:lang="sl">Slovensko zdravniško društvo (SZD)</copyright-holder>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="en">
               <license-p>This is an open access article distributed under the terms of the
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Attribution-NonCommercial
            License</ext-link>, which permits unrestricted use, distribution, and
          reproduction in any medium, provided the original author and source are
          credited and only for non-commercial purposes. </license-p>
            </license>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="sl">
               <license-p>To je članek z odprtim dostopom, ki ga lahko uporabite pod pogoji iz
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Priznanje avtorstva-Nekomercialno
            licence</ext-link>. ki dovoljuje distribucijo, predelavo ali
          prilagoditev, ter gradijo na njem, v nekomercialne namene, z navedbo avtorja
          in izvirnega dela.</license-p>
            </license>
         </permissions>
         <abstract xml:lang="sl">
            <title>Izvleček</title>
            <p>Izhodišče: Anemija zaradi pomanjkanja železa, tj. sideropenična anemija (v nadaljevanju SDA), je najpogostejša med anemijami in pogost vzrok napotitve v hematološko ambulanto. Z raziskavo smo želeli ugotoviti, koliko bolnikov s SDA smo v dveletnem obdobju obravnavali v Hematološki ambulanti UKC Ljubljana (v nadaljevanju ambulanta KOH). Zanimal nas je vzrok napotitve, značilnosti bolnikov in njihove krvne slike ob prvem pregledu, vrsta terapije, ki so jo prejeli, ter število in razlog kontrolnih pregledov. V prispevku se osredinjamo na prepoznavanje SDA, diagnosticiranje in možnosti zdravljenja ter obravnavo bolnikov v primeru, da z nadomeščanjem z železom ni ustreznega hematološkega odziva.</p>
            <p>Metode: Retrospektivno smo analizirali dokumentacijo bolnikov, ki so bili med 1. 1. 2014 in 31. 12. 2015 pregledani v ambulanti KOH in pri katerih smo na osnovi klinične slike ter upoštevaje laboratorijske vrednosti postavili diagnozo SDA. Podatke smo zbrali z računalniškim informacijskim sistemom Hipokrat in jih statistično ovrednotili z računalniškim programom Excel.</p>
            <p>Rezultati: Med 1. 1. 2014 in 31. 12. 2015 je bilo v ambulanti KOH pregledanih 277 bolnikov, pri katerih je bila po pregledu ugotovljena SDA. Obravnavali smo 11,6 % moških in 88,4 % žensk. Žensk v rodni dobi je bilo 62,5 %. SDA je bila kot napotna diagnoza v specialistično ambulanto navedena zgolj v 39 %, v ostalih primerih stanja napotni zdravnik ni prepoznal. Pridružene bolezni smo beležili pri 50,2 % bolnikov. 62,5 % bolnikov je bilo naročenih na kontrolni pregled k hematologu. 63,5 % vseh bolnikov je bilo v ambulanti KOH ob prvem pregledu zdravljenih z intravenskim pripravkom železa. Transfuzijo koncentriranih eritrocitov je ob prvem pregledu prejelo 4,3 % bolnikov.</p>
            <p>Zaključek: V dveletnem obdobju smo v ambulanti KOH pogosto obravnavali bolnike s SDA. Podatki kažejo, da napotni zdravniki slabo prepoznavajo to najpogostejšo anemijo. SDA ni krvna bolezen. Napotitev bolnikov s SDA v ambulanto KOH je upravičena pri hudi mikrocitni anemiji, neodzivnosti na peroralno in/ali intravensko nadomestno zdravljenje z železom in pri tistih bolnikih, pri katerih pridružena sprememba v krvni sliki vztraja kljub učinkovitemu zdravljenju s pripravki železa.</p>
         </abstract>
         <trans-abstract xml:lang="en">
            <title>Abstract</title>
            <p>Background: Iron deficiency anaemia (IDA) is the most prevalent type of anaemia and a common cause for patient referrals to the haematology outpatient clinic. The aim of this study was to determine the number of patients with IDA treated at the Haematology Outpatient Clinic of the UMC Ljubljana in the period of two years, as well as to inquire into the causes for their referrals to the clinic, patient characteristics, their complete blood count results at initial examination, the prescribed therapy, the number and the causes of their follow-up visits. We draw special attention to the IDA onset mechanism, the microcytic anaemia therapy principles and the indications prompting a referral of an IDA patient to the haematology specialist.</p>
            <p>Methods: We undertook a retrospective analysis of the medical records of patients who were referred to the Haematology outpatient clinic of the UMC Ljubljana for examination in the two-year period between 1 January 2014 and 31 December 2015 and had been diagnosed with IDA on the basis of their clinical picture and their CBC values. Data were collected with the Hipokrat IT system and statistically evaluated with Microsoft Excel.</p>
            <p>Results: In the period relevant for our research, 277 patients of those who were referred to the Haematology outpatient clinic for medical examination were diagnosed with IDA. 11.6 % of these patients were male and 88.4 % female; 62.1 % of the female patients were of childbearing age. IDA was specified as the referral diagnosis in the cases of no more than 39 % of the patients referred to the specialist outpatient clinic, whilst the medical condition of the remaining percentage of patients was not identified by the referring doctor. Comorbidities were observed in 50.2 % of the patients, and for 62.5 % of the patients a follow-up appointment was scheduled by the treating haematologist. Of all patients, 63.5 % were treated with an intravenous iron preparation during their first examination at the outpatient clinic and a transfusion of erythrocytes was administered during such an examination to 4.3 % of the patients.</p>
            <p>Conclusion: Patients with IDA were often treated at our Haematology Outpatient Clinic in the relevant two-year period. The data indicates a poor recognition rate of this prevalent type of anaemia. IDA is not a blood disorder and the referral of IDA patients to the Haematology Outpatient Clinic is justified in the case of severe microcytic anaemia, when the patient does not respond to the oral or intravenous iron replacement therapy or if a concomitant change in the CBC persists despite the effective treatment with iron preparations.</p>
         </trans-abstract>
         <kwd-group xml:lang="sl">
            <kwd>anemija zaradi pomanjkanja železa</kwd>
            <kwd>mikrocitna anemija</kwd>
            <kwd>anemija kroničnega vnetja</kwd>
            <kwd>hepcidin</kwd>
            <kwd>nadomeščanje z železovimi pripravki</kwd>
         </kwd-group>
         <kwd-group xml:lang="en">
            <kwd>iron deficiency anaemia</kwd>
            <kwd>microcytic anaemia</kwd>
            <kwd>anaemia of chronic disease</kwd>
            <kwd>hepcidin</kwd>
            <kwd>iron supplements</kwd>
         </kwd-group>
      </article-meta>
   </front>
   <body>
      <sec id="s1" sec-type="Uvod">
         <label>1</label>
         <title>Uvod</title>
         <p>Anemija zaradi pomanjkanja železa je edina anemija, ki v enakem obsegu prizadene tako revne kot bogate sloje. V razvitem svetu je pogostejša pri ženskah v rodni dobi zaradi obilnih menstruacij (<xref ref-type="bibr" rid="b1">1</xref>). Pogosteje jo ugotavljamo pri osebah, ki redno jemljejo nesteroidne antirevmatike in zaviralce protonske črpalke, slednje verjetno zaradi ulkusne bolezni in zmanjšanja kislosti želodčnega soka (<xref ref-type="bibr" rid="b2">2</xref>). Pomanjkljiva prehrana je redko vzrok SDA v razvitem svetu. Lahko pa se pojavi pri ljudeh, ki se poslužujejo nenavadnih diet (<xref ref-type="bibr" rid="b1">1</xref>). Vzroki so tudi skrajno nenavadni; anemijo zaradi pomanjkanja železa lahko najdemo pri bolnikih s sindromom Münchausen (<xref ref-type="bibr" rid="b3">3</xref>). V deželah tretjega sveta na račun pomanjkljive prehrane in parazitskih okužb prizadane predvsem otroke, mladostnike in nosečnice (<xref ref-type="bibr" rid="b1">1</xref>). Ko SDA ugotovimo moškim ali ženskam v menopavzi, je prva misel izključiti raka prebavil (<xref ref-type="bibr" rid="b4">4</xref>). Zdravljenje z nadomeščanjem železa je pri SDA zgolj simptomatski ukrep. Ključno je poiskati vzrok in ga odpraviti. V prispevku predstavljamo rezultate analize bolnikov, ki so bili v dveletnem obdobju napoteni v ambulanto KOH z napotno diagnozo SDA, in tistih, pri katerih smo z anamnezo in kliničnim pregledom, upoštevajoč laboratorijske izvide, odkrili SDA. V prispevku se osredinjamo na prepoznavanje te anemije, diagnosticiranje vzrokov, možnosti zdravljenja z oralnimi in intravenskimi železovimi pripravki ter obravnavo bolnikov v primeru, da z nadomeščanjem ni ustreznega odziva.</p>
      </sec>
      <sec id="s2" sec-type="Material in metode">
         <label>2</label>
         <title>Material in metode</title>
         <p>Retrospektivno smo analizirali popise 277 bolnikov, ki so bili med 1.1. 2014 in 31.12. 2015 napoteni v ambulanto KOH zaradi SDA, vključno tiste bolnike, pri katerih smo v hematološki ambulanti s kliničnim pregledom, upoštevajoč laboratorijske izvide, postavili diagnozo SDA. Zanimala nas je starost in spol bolnikov, napotna diagnoza, prisotnost simptomov in znakov anemije, vrednost hemoglobina, eritrocitov, povprečne prostornine eritrocita (PVE), serumskega železa, celotne vezalne sposobnosti seruma za železo (<italic toggle="yes">angl</italic>
            <italic toggle="yes">.</italic> total iron binding capacity, TIBC), serumskega feritina in pridružene spremembe v krvni sliki, pri ženskah pa prisotnost menopavze. Beležili smo morebitno pridruženost kroničnih bolezni in vnetij, ki bi lahko vplivale na sočasen pojav anemije kroničnega vnetja. V ta namen smo poleg anamneze zabeležili druge bolnikove pridružene bolezni, vrednosti vnetnih parametrov, ledvičnih retentov in jetrnih encimov. Zanimalo nas je, koliko bolnikov je bilo naročenih na kontrolni pregled v ambulanto KOH in kaj je bil razlog za kontrolni pregled, kakšno zdravljenje je bolnikom pred prihodom v ambulanto KOH predpisal izbrani zdravnik in kakšnega zdravljenja so bili deležni ob prvem pregledu v ambulanti KOH. V <xref ref-type="table" rid="table1">Tabeli 1</xref> je opisana uporabljena razdelitev anemije glede na vrednost hemoglobina. Podatke za raziskavo smo zbrali z računalniškim informacijskim sistemom Hipokrat in jih statistično ovrednotili z računalniškim programom Excel.</p>
         <p>V raziskavi smo uporabili naslednje referenčne vrednosti:</p>
         <table-wrap position="anchor" id="table1" orientation="portrait">
            <label>Tabela 1:</label>
            <caption>
               <p> Razdelitev anemij glede na vrednost hemoglobina.</p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <th rowspan="1" colspan="1">Razdelitev anemij</th>
                     <th rowspan="1" colspan="1">koncentracija hemoglobina</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td rowspan="1" colspan="1">Blaga</td>
                     <td rowspan="1" colspan="1">
                        <p>100–120 g/L (ženske)</p>
                        <p>100–130 g/L (moški)</p>
                     </td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Zmerna</td>
                     <td rowspan="1" colspan="1">70–100 g/L</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Huda</td>
                     <td rowspan="1" colspan="1">&lt; 70 g/L</td>
                  </tr>
               </tbody>
            </table>
         </table-wrap>
         <list>
            <list-item>
               <label>•</label>
               <p>Hemoglobin: 120–160 g/L za ženske in 130–180 g/L za moške (<xref ref-type="bibr" rid="b5">5</xref>).</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>Hematokrit: 0,30–0,47 za ženske in 0,40–0,54 za moške; povprečni volumen (PVE): 82–98 fL; eritrociti: 4,2–5,4 × 10<sup>12</sup>/L za ženske in 5,4–6,3 × 10<sup>12</sup>/L za moške; levkociti: 3,9–11,1 × 10<sup>9</sup>/L; trombociti: 157–384 × 10<sup>9</sup>/L (<xref ref-type="bibr" rid="b6">6</xref>).</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>Serumsko železo: 10,7–28,6 µmol/L; feritin: 10–120 μg/L za ženske in 20–300 μg/L za moške; totalna vezalna sposobnost za železo (TIBC): 44,8–80,6 µmol/L; povišan C-reaktivni protein: vrednost nad 5 mg/L; kreatinin: 44–97 µmol/L; povišana aspartatna transaminaza (AST): 3-kratna zgornja meja (0,52 µkat/L) za ženske in 3-kratna zgornja meja (0,58 µkat/L) za moške; povišana alaninska transaminaza (ALT): 3-kratna zgornja meja (0,56 µkat/L) za ženske in 3-kratna zgornja meja (0,74 µkat/L) za moške (<xref ref-type="bibr" rid="b7">7</xref>).</p>
            </list-item>
         </list>
         <p>Raziskavo je odobrila Komisija za medicinsko etiko RS dne 14. 11. 2017 (sklep št. 0120–583/2017/5).</p>
      </sec>
      <sec id="s3" sec-type="Rezultati">
         <label>3</label>
         <title>Rezultati</title>
         <p>Analizirali smo obravnavo 277 bolnikov, pregledanih od 1.1. 2014 do 31.12. 2015 v ambulanti KOH, pri katerih smo ugotovili anemijo zaradi pomanjkanja železa. Moških je bilo 32 (11,6 %). Ženske so bile zastopane v 88,4 % (245). 172 (62,1 %) žensk je bilo v rodni dobi in 73 (26,3 %) žensk v menopavzi. Mediana starosti pri moških je bila 66,5 let (razpon 21–87 let). Mediana starosti pri ženskah je bila 44 let (razpon od 18–94 let). V <xref ref-type="table" rid="table2">Tabeli 2</xref> so predstavljeni izsledki povprečnih vrednosti kazalcev rdeče krvne slike. Večina napotenih bolnikov je imela vrednosti hemoglobina v območju blage in zmerne anemije. Malo manj kot petina pregledanih bolnikov je imela vrednost hemoglobina v referenčnem območju. <xref ref-type="fig" rid="fig1">Slika 1</xref> prikazuje porazdelitev anemij glede na vrednost hemoglobina.</p>
         <table-wrap position="anchor" id="table2" orientation="portrait">
            <label>Tabela 2:</label>
            <caption>
               <p> Povprečne vrednosti kazalcev rdeče krvne slike in stanja železa.</p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <th rowspan="1" colspan="1">Laboratorijski kazalci</th>
                     <th rowspan="1" colspan="1">Ženske</th>
                     <th rowspan="1" colspan="1">Moški</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td rowspan="1" colspan="1">Povprečna vrednost hemoglobina (g/L)</td>
                     <td rowspan="1" colspan="1">100,5 (σ = ± 20,4)</td>
                     <td rowspan="1" colspan="1">101,5 (σ = ± 23,3)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Povprečna vrednost eritrocitov (10<sup>12</sup>/L)</td>
                     <td rowspan="1" colspan="1">4,18 (σ = ± 0,62)</td>
                     <td rowspan="1" colspan="1">4,13 (σ = ± 0,95)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Povprečna vrednost serumskega železa (µmol/L)</td>
                     <td colspan="2" rowspan="1">8,3 (σ = ± 10,9)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Povprečna vrednost feritina (μg/L )</td>
                     <td colspan="2" rowspan="1">21,6 (σ = ± 70,5)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Povprečna vrednost TIBC (µmol/L)</td>
                     <td colspan="2" rowspan="1">71,3 (σ = ± 10,6)</td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <p>TIBC – angl. totalna vezalna sposobnost za železo, σ – standardni odklon</p>
            </table-wrap-foot>
         </table-wrap>
         <fig position="anchor" id="fig1" orientation="portrait">
            <label>Slika 1:</label>
            <caption>
               <p> Porazdelitev anemij glede na vrednost hemoglobina. N = 277</p>
            </caption>
            <p>
               <graphic xlink:href="2523-web-resources/image/zdravvestn-2523-sl-01.png"
                        position="float"
                        orientation="portrait"/>
            </p>
         </fig>
         <p>Bolnike so izbrani zdravniki napotili z napotnimi diagnozami, ki so po pogostosti opisane v <xref ref-type="table" rid="table3">Tabeli 3</xref>.</p>
         <table-wrap position="anchor" id="table3" orientation="portrait">
            <label>Tabela 3:</label>
            <caption>
               <p> Najpogostejše napotne diagnoze bolnikov z ugotovljeno SDA v hematološki ambulanti.</p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <th rowspan="1" colspan="1">Napotna diagnoza</th>
                     <th rowspan="1" colspan="1">n = 277 (%)</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td rowspan="1" colspan="1">Anemija zaradi pomanjkanja železa</td>
                     <td rowspan="1" colspan="1">108 (39)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Mikrocitna anemija</td>
                     <td rowspan="1" colspan="1">77 (27,8)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Anemija</td>
                     <td rowspan="1" colspan="1">30 (10,8)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Levkopenija</td>
                     <td rowspan="1" colspan="1">5 (1,8)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Trombocitopenija</td>
                     <td rowspan="1" colspan="1">5 (1,8)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Pomanjkanje železa</td>
                     <td rowspan="1" colspan="1">4 (1,4)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Bicitopenija</td>
                     <td rowspan="1" colspan="1">4 (1,4)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Normocitna anemija</td>
                     <td rowspan="1" colspan="1">4 (1,4)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Ostalo</td>
                     <td rowspan="1" colspan="1">40 (14,6)</td>
                  </tr>
               </tbody>
            </table>
         </table-wrap>
         <p>Preostale napotne diagnoze so bile potenje, monoklonski zobec, slabo počutje, monoklonski imunoglobulin nedoločenega pomena (MINP), sum na mielodisplastični sindrom (MDS), sum na talasemijo, pancitopenija, kronična anemija, makrocitoza, pomanjkanje vitamina B12, periferna nevropatija, sum na hemolitično anemijo, pozitivni Coombsov test, zlatenica idr.</p>
         <p>Po mnenju izbranega zdravnika je bil pregled nujen pri 12 bolnikih (4,3 %). Med njimi je imel 1 bolnik blago anemijo, 7 bolnikov zmerno in 6 bolnikov hudo anemijo.</p>
         <p>V kliničnem statusu ob pregledu v ambulanti KOH je bila kot edini znak anemije opisana bledica kože. Zabeležili smo jo pri 145 (52,3 %) bolnikov.</p>
         <p>Kot je razvidno iz <xref ref-type="table" rid="table4">Tabele 4</xref>, so bile anemiji pogosto pridružene druge spremembe v krvni sliki.</p>
         <table-wrap position="anchor" id="table4" orientation="portrait">
            <label>Tabela 4:</label>
            <caption>
               <p> Porazdelitev najpogostejših pridruženih sprememb v krvni sliki.</p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <th rowspan="1" colspan="1">Pridružena sprememba v krvni sliki</th>
                     <th rowspan="1" colspan="1">n = 277 (%)</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td rowspan="1" colspan="1">Levkopenija</td>
                     <td rowspan="1" colspan="1">21 (7,6)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Levkocitoza</td>
                     <td rowspan="1" colspan="1">16 (5,8)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Trombocitopenija</td>
                     <td rowspan="1" colspan="1">20 (7,2)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Trombocitoza</td>
                     <td rowspan="1" colspan="1">46 (16,6)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Pancitopenija</td>
                     <td rowspan="1" colspan="1">4 (1,4)</td>
                  </tr>
               </tbody>
            </table>
         </table-wrap>
         <p>Iz <xref ref-type="table" rid="table5">Tabele 5</xref> ugotovimo, da smo vsaj eno pridruženo bolezen ugotavljali pri 139 (50,2 %) napotenih bolnikov.</p>
         <table-wrap position="anchor" id="table5" orientation="portrait">
            <label>Tabela 5:</label>
            <caption>
               <p> Pridružene bolezni bolnikov s SDA. </p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <th rowspan="1" colspan="1">Pridružena bolezen/stanje</th>
                     <th rowspan="1" colspan="1">n = 277 (%)</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td rowspan="1" colspan="1">Sladkorna bolezen tipa 2</td>
                     <td rowspan="1" colspan="1">23 (8,3)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Avtoimunska bolezen*</td>
                     <td rowspan="1" colspan="1">23 (8,3)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Hipotiroza</td>
                     <td rowspan="1" colspan="1">18 (6,5)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Rak</td>
                     <td rowspan="1" colspan="1">8 (2,9)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Srčno popuščanje</td>
                     <td rowspan="1" colspan="1">8 (2,9)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Okultna krvavitev iz prebavil</td>
                     <td rowspan="1" colspan="1">6 (2,2)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Nosečnost</td>
                     <td rowspan="1" colspan="1">5 (1,8)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Kronična ledvična odpoved</td>
                     <td rowspan="1" colspan="1">3 (1,1)</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Drugo</td>
                     <td rowspan="1" colspan="1">69 (24,9)</td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <p>* ulcerozni kolitis, Chronova bolezen, revmatoidni artritis, tiroiditis Hashimoto, celiakija, Sjögrenov sindrom, sistemska skleroza, sladkorna bolezen tipa 1</p>
            </table-wrap-foot>
         </table-wrap>
         <p>Tri ali več pridruženih bolezni je imelo 35 (12,6 %) bolnikov.</p>
         <p>Pri skupini bolnikov, pri katerih smo z anamnezo ugotavljali kronične bolezni, smo povišan C-reaktivni protein zabeležili pri 54 (19,5 %) bolnikih, nepravilnosti jetrnih transaminaz pri 5 (1,8 %) bolnikih in povišano vrednost sečnine in kreatinina pri eni bolnici. Pri 4 bolnicah (1,4 %) je hematolog v izvidih navedel poleg diagnoze SDA tudi anemijo kroničnega vnetja.</p>
         <p>Na kontrolni pregled pri hematologu je bilo naročenih 173 (62,5 %) bolnikov. Razlog kontrolnega pregleda je bil pri 133 (48 %) bolnikih kontrola krvne slike po zdravljenju z železovimi pripravki. V 144 (52 %) primerih se je hematolog odločil za nadaljnje diagnostične ukrepe v sklopu SDA.</p>
         <p>163 (58,8 %) bolnikov se je zaradi SDA zdravilo bodisi v preteklosti ali pa je železo prejemalo ob prvem obisku v ambulanti. 144 (52 %) bolnikov se je zdravilo z oralnimi pripravki železa. 30 (10,8 %) jih je prejelo intravenske pripravke. 9 (3,2 %) bolnikov je prejelo transfuzijo koncentriranih eritrocitov. Za ostale bolnike ni podatka. 210 (75,8 %) vseh pregledanih bolnikov je prejelo zdravljenje oz. navodila za zdravljenje. Med njimi je 176 (83,9 %) bolnikov prejelo intravenski pripravek železa in 12 (5,5 %) bolnikov transfuzijo koncentriranih eritrocitov. 9 (30 %) bolnikov, ki so ob prvem ambulantnem pregledu prejeli intravensko železo, so prejeli še drugi odmerek intravenskega železa v ambulanti KOH. Med bolniki, ki so bili najprej zdravljeni z oralnimi pripravki železa, jih je 41 (28,5 %) nadaljevalo z oralnim nadomeščanjem železa tudi po kontrolnem pregledu. Transfuzijo koncentriranih eritrocitov je ob kontrolnem pregledu prejelo 9 (2,9 %) bolnikov.</p>
      </sec>
      <sec id="s4" sec-type="Razpravljanje">
         <label>4</label>
         <title>Razpravljanje</title>
         <p>Anemija zaradi pomanjkanja železa je najpogostejša med anemijami in v osnovi ni krvna bolezen. V raziskavi smo ugotovili, da smo v dveletnem obdobju v KOH obravnavali 277 bolnikov s SDA, torej 2,7 bolnika s SDA na dan. Med obravnavanimi bolniki so bile najštevilčnejše ženske v rodni dobi. Verjeten vzrok anemije pri tej populaciji je izguba krvi ob menstruacijah.</p>
         <p>Absorpcija železa je omejena na 1–2 mg dnevno, saj železo, potrebno za eritropoezo pridobimo predvsem preko metabolnega obrata makrofagov, ki fagocitirajo nefunkcionalne eritrocite (<xref ref-type="bibr" rid="b1">1</xref>). Pri klinično pomembnem pomanjkanju železa se sprva izpraznijo zaloge železa, kar beležimo kot padec vrednosti serumskega feritina (<xref ref-type="bibr" rid="b8">8</xref>). Po izpraznitvi zalog železa nastanejo motnje sinteze hemoglobina, v kostnem mozgu pa nastajajo hipokromni mikrocitni eritrociti. Kot je razvidno v <xref ref-type="fig" rid="fig2">Sliki 2</xref>, se klinično pomembno pomanjkanje železa razvije postopoma.</p>
         <fig position="anchor" id="fig2" orientation="portrait">
            <label>Slika 2:</label>
            <caption>
               <p> Razvoj laboratorijskih sprememb ob pojavu negativne bilance železa. </p>
            </caption>
            <p>
               <graphic xlink:href="2523-web-resources/image/zdravvestn-2523-sl-02.png"
                        position="float"
                        orientation="portrait"/>
            </p>
            <p>(TIBC – totalna vezalna sposobnost za železo, angl. total iron binding capacity; RDW – variabilnost širine eritrocitov, angl. red cell distributon width). Povzeto po Alleyne in sodelavci (<xref ref-type="bibr" rid="b8">8</xref>).</p>
         </fig>
         <p>Izguba železa pri ženskah v rodni dobi se ocenjuje na 1–3 mg dnevno, vnos pa je pogosto prenizek za vzdrževanje ničelne bilance železa (<xref ref-type="bibr" rid="b1">1</xref>). Poleg obilnih menstruacij so v razvitem svetu najpogostejši razlogi za SDA krvavitev iz prebavil, motena absorpcija železa in nenavadne diete (<xref ref-type="bibr" rid="b1">1</xref>). V nerazvitem svetu se SDA najpogosteje pojavi ob pomanjkljivi prehrani zaradi revščine tamkajšnjega prebivalstva.</p>
         <fig position="anchor" id="fig3" orientation="portrait">
            <label>Slika 3:</label>
            <caption>
               <p> Predlog diagnostičnega postopka ob mikrocitni anemiji.</p>
            </caption>
            <p>
               <graphic xlink:href="2523-web-resources/image/zdravvestn-2523-sl-03.png"
                        position="float"
                        orientation="portrait"/>
            </p>
            <p>(PVE – povprečni volumen eritorcitov, Eri – eritrociti, TIBC – angl. total iron binding capacity, totalna vezalna sposobnost za železo, N – normalno).</p>
         </fig>
         <p>Pri ženskah z menoragijo moramo pomisliti na motnjo primarne hemostaze (<xref ref-type="bibr" rid="b9">9</xref>). Medtem ko von Wilebrandova bolezen prizadane okoli 1 % populacije, jo pri ženskah z menoragijo ugotavljamo v več kot 5 % (<xref ref-type="bibr" rid="b10">10</xref>). Prav tako so pri ženskah z menoragijo pogostejše motnje v delovanju trombocitov (<xref ref-type="bibr" rid="b9">9</xref>). Nadaljnje diagnosticiranje pri ženskah s SDA pred menopavzo je v domeni družinskega zdravnika in ginekologa. Tudi pri mlajših ženskah s SDA je v ozadju lahko prikrita krvavitev iz prebavil. Zato je potrebno opraviti presejalno testiranje krvi v blatu vsaj šestkrat zaporedoma.</p>
         <p>Tretjina obravnavanih bolnikov s SDA v hematološki ambulanti so bili po izsledkih raziskave starejši moški in ženske v menopavzi. Pri njih je verjetnost za vzrok bolezni v prebavilih velika (<xref ref-type="bibr" rid="b1">1</xref>). Obvezna je gastroenterološka diagnostika (<xref ref-type="bibr" rid="b4">4</xref>). Z endoskopskimi preiskavami izključujemo morebitno maligno bolezen v prebavilih, prisotnost vnetja in razjed po sluznici prebavil ter angiodisplazije (<xref ref-type="bibr" rid="b1">1</xref>). Tudi krvavitev iz hemeroidov je lahko vzrok za SDA. Ko izključimo krvavitev iz prebavil, je potrebno pri bolnikih vseh starosti pomisliti na moteno absorpcijo železa, ki je lahko posledica okužbe z bakterijo <italic toggle="yes">H. pylori</italic>, celiakije ali kroničnih vnetnih črevesnih bolezni. Redkeje je izvor krvavitev v sečilih. Pri obeh spolih je pomembna anamneza o nenavadnih dietah in zdravilih, ki jih bolnik prejema (<xref ref-type="bibr" rid="b11">11</xref>). SDA se lahko pojavi ob uživanju nesteroidnih antirevmatikov, salicilatov, varfarina, klopidogrela, heparina, glukokortikoidov in zaviralcev protonske črpalke (<xref ref-type="bibr" rid="b1">1</xref>). Anemija ni bolezen, temveč simptom, pri katerem je potrebno ugotoviti vzrok njenega nastanka.</p>
         <p>Iz <xref ref-type="table" rid="table3">Tabele 3</xref> razberemo, da je bila povprečna raven hemoglobina pri vključenih moških in ženskah na meji med blago in zmerno anemijo. Povprečna raven serumskega železa je bila pričakovano zmanjšana, povprečna raven serumskega feritina na spodnji meji normale, povprečna raven TIBC še v okviru referenčnih vrednosti. Zanimivo je, da je imela skoraj petina bolnikov ob prvem pregledu v ambulanti KOH normalno raven hemoglobina. Slednje pripisujemo ukrepanju triažnega hematologa, ki ob triaži, upoštevajoč priložene laboratorijske izvide, pošlje navodila izbranemu zdravniku še pred prvim pregledom bolnika s SDA v ambulanti KOH.</p>
         <p>V raziskavi preseneča delež bolnikov, napotenih kot nujni primeri. Pri polovici teh bolnikov je bila raven hemoglobina v območju zmerne anemije, ena bolnica je imela raven hemoglobina celo v območju blage anemije.</p>
         <p>Iz <xref ref-type="table" rid="table4">Tabele 4</xref> je razvidno, da je bila malo manj kot polovica bolnikov v ambulanto KOH napotena kot SDA. Zgolj desetina le-teh je imela raven hemoglobina v območju hude anemije. Indikacije za napotitev bolnika s SDA k specialistu hematologu so huda mikrocitna anemija (Hb pod 70 g/L), negotovost pri razmejitvi SDA od anemije kroničnega vnetja (AKV) ter druge nepravilnosti v krvni sliki, ki se kljub nadomestnemu zdravljenju z železom in dvigu ravni hemoglobina ne popravljajo.</p>
         <p>SDA ostaja slabo prepoznana anemija. Kar tretjina bolnikov je bila napotena z diagnozo ‘mikrocitna anemija’. Podatek preseneča, saj je SDA daleč najpogostejši vzrok mikrocitne anemije. Poleg znižane vrednosti ravni hemoglobina in spremljajoče mikrocitoze za potrditev diagnoze SDA potrebujemo še dokaz zmanjšanih zalog železa v telesu, tj. znižana vrednost serumskega železa in zmanjšan serumski feritin (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b11">11</xref>). PVE je nespecifični kazalec, saj normocitna anemija pomanjkanja železa ne izključuje (<xref ref-type="bibr" rid="b12">12</xref>). Pri bolnikih je potrebno pomisliti na kombinacijo SDA in pomanjkanje vitamina B12 ali folatov. Poleg SDA v diferencialno diagnozo mikrocitne anemije sodi še anemija kroničnega vnetja in talasemija minor (<xref ref-type="bibr" rid="b11">11</xref>).</p>
         <p>Anemija kroničnega vnetja je anemija, ki se pojavi ob kroničnih boleznih, kroničnih okužbah in vnetjih ter ob malignih boleznih (<xref ref-type="bibr" rid="b11">11</xref>). Značilna je povišana raven hormona hepcidina, kar onemogoči absorpcijo železa iz prebavil in sproščanje železa iz zalog v telesu. Zato v laboratorijskih izvidih vidimo zmanjšano koncentracijo serumskega železa, povišano koncentracijo serumskega feritina in pogosto nizko koncentracijo TIBC. Za oceno zalog železa vrednost serumskega feritina pri AKV ni povedna (<xref ref-type="bibr" rid="b1">1</xref>
            <xref ref-type="bibr" rid="b3">3</xref>).</p>
         <p>Talasemija beta minor je pri nas najpogostejša hemoglobinopatija (<xref ref-type="bibr" rid="b14">14</xref>). V Sloveniji se pojavlja predvsem pri osebah z mediteranskimi ali balkanskimi predniki. Verjetno bo v prihodnosti bistveno pogostejša zaradi migracijskih tokov. Bolnik s talasemijo beta minor je praviloma brez kliničnih težav. V krvni sliki je prisotna blaga anemija (vrednost hemoglobina okoli 100 g/L) z izrazito mikrocitozo (PVE med 60 in 70 fl) ob normalni vrednosti eritrocitov (<xref ref-type="bibr" rid="b15">15</xref>). Opazno je nesorazmerje med ravnijo hemoglobina in izrazito mikrocitozo. V razmazu periferne krvi najdemo tarčaste eritrocite, bazofilne punktacije v eritrocitih, pogostejši so dakriociti in ovalociti (<xref ref-type="bibr" rid="b16">16</xref>). Bolniku ob sumu na talasemijo minor prizanesemo z neprijetnimi endoskopskimi preiskavami in nepravilnost potrdimo z elektroforezo hemoglobina.</p>
         <p>Ob ugotovitvi mikrocitne anemije je potrebno ovrednotiti status železa v krvi (<xref ref-type="bibr" rid="b11">11</xref>). Slednje razumemo kot določitev vrednosti serumskega železa, serumskega feritina in TIBC. Pri SDA je vrednost serumskega železa in serumskega feritina nizka, vrednost TIBC pa visoka. Zmanjšana vrednost feritina je najbolj zanesljiv test za potrditev anemije zaradi pomanjkanja železa (<xref ref-type="bibr" rid="b17">17</xref>). Normalna vrednost serumskega feritina ob nizkem serumskem železu ne izključujeta SDA, saj je SDA lahko pridružena AKV (<xref ref-type="bibr" rid="b11">11</xref>,<xref ref-type="bibr" rid="b13">13</xref>).</p>
         <p>Homeostaza železa je nadzorovan proces. Glavno vlogo igra hormon hepcidin, ki se nahaja v jetrih (<xref ref-type="bibr" rid="b11">11</xref>). Velika plazemska koncentracija železa sproži izločanje hepcidina iz jeter. Preko vezave na feroportin, transmembranski prenašalec železa, vpliva na razpad le-tega in tako zavre absorpcijo železa iz duodenuma in privzem iz retikuloendotelijskega sistema v kri. Kronična vnetja in okužbe preko imunskih mehanizmov prav tako povečajo izločanje hepcidina iz jeter in zato zmanjšajo raven serumskega železa, ki ga je v zalogah sicer dovolj. Stanje imenujemo funkcionalno pomanjkanja železa. Od manifestnega pomanjkanja se razlikuje tako, da so pri funkcionalnem zaloge železa velike, kar prepoznamo kot zvečano vrednost serumskega feritina.</p>
         <p>Klinične raziskave zaključujejo, da je pomanjkanja železa pri kroničnih boleznih prisotno, če je vrednost feritina manjša od 100 μg/L (<xref ref-type="bibr" rid="b1">1</xref>
            <xref ref-type="bibr" rid="b8">8</xref>). Mnenja so deljena. Nekateri menijo, da je ta vrednost 200 μg/L (<xref ref-type="bibr" rid="b2">2</xref>,<xref ref-type="bibr" rid="b19">19</xref>). Dokončnega priporočila ni. V Sloveniji se pri AKV železo nadomešča, kolikor je vrednost feritina manjša od 100 μg/L. Oralni pripravki železa pri AKV niso učinkoviti, zato železo nadomeščamo vedno intravensko (<xref ref-type="bibr" rid="b19">19</xref>,<xref ref-type="bibr" rid="b20">20</xref>).</p>
         <p>V raziskavi smo pri tretjini bolnikov zabeležili pridružene kronične bolezni. Pri opredelitvi kombiniranih vzrokov za mikrocitno anemijo so nam v pomoč drugi laboratorijski parametri. To so zasičenost transferina, vrednost topnega transferinskega receptorja, koncentracija hemoglobina v retikulocitih in raven hepcidina (<xref ref-type="bibr" rid="b19">19</xref>). Določamo jih v laboratoriju KOH, v klinični praksi pa jih redkeje uporabljamo.</p>
         <p>Zmanjšana raven serumskega železa lahko sovpada s pomanjkanjem železa. Za oceno zalog železa pa ni primerna, saj je odvisna od posameznikove diete. Bolnik z SDA, ki zaužije obrok z visoko vsebnostjo železa, ima v krvi lahko povečano ali normalno raven serumskega železa. Vrednost lahko zdravnika zavede, kakor da so zaloge železa zadostne, dejansko pa je raven feritina, ki je kazalec zaloge v odsotnosti AKV, zmanjšana. Zaradi dnevne variabilnosti je raven serumskega železa največja zjutraj in opoldne, v popoldnevu pa se postopoma manjša (<xref ref-type="bibr" rid="b21">21</xref>). Železo je odlično hranilo za mikroorganizme. Zato imajo posamezniki z veliko vrednostjo serumskega železa pogostejše okužbe in septična stanja (<xref ref-type="bibr" rid="b35">35</xref>,<xref ref-type="bibr" rid="b36">36</xref>).</p>
         <p>Bolniki prihajajo v ambulanto KOH z izvidom krvne slike in določeno vrednostjo serumskega železa, a brez podatka o vrednosti serumskega feritina. Pri obravnavi SDA je to ključnega pomena, zato ga je ob napotitvi bolnika potrebno priložiti bolnikovi dokumentaciji.</p>
         <p>Klinična slika bolnika z anemijo je poznana. Ključen je podatek o hitrosti nastanka anemije. Če je anemija kronična, so tudi bolniki s hudo mikrocitno anemijo neredko brez simptomov. Po lastnih izkušnjsah z Jehovovimi pričami smo to populacijsko skupino videvali na kontrolnih pregledih, dokler raven hemoglobina ni bila manjša od 40 g/L. V naši raziskavi je imela zgolj polovica bolnikov, pregledanih v hematološki ambulanti, opisano bledico kože. Gre za subjektivno oceno lečečega hematologa. V kliničnem statusu bolnikov se le-ta redko opiše, kar pripisujemo dejstvu, da je zaradi gneče v hematoloških ambulantah delo zdravnika prehitro in tako tudi nenatančno. Za nadomeščanje z železom se odločimo tudi pri bolnikih, ki navajajo izrazito utrujenost, dispnejo ob naporu in palpitacije.</p>
         <p>Iz <xref ref-type="table" rid="table4">Tabele 4</xref> je razvidno, da je imelo v raziskavi veliko bolnikov ob anemiji še drugo nepravilnost v krvni sliki. SDA pogosto spremljajo pridružene spremembe v krvni sliki (<xref ref-type="bibr" rid="b22">22</xref>). Najpogostejša je bila reaktivna trombocitoza. Prisotna je bila pri šestini vseh obravnavanih bolnikov. Mehanizem nastanka reaktivne trombocitoze ob SDA še ni poznan (<xref ref-type="bibr" rid="b23">23</xref>). Nekateri avtorji menijo, da gre za sinergistični vpliv eritropoetina na trombopoezo (<xref ref-type="bibr" rid="b24">24</xref>). Ob anemiji in trombocitozi je smiselno opraviti preiskave železa v periferni krvi, saj se lahko v ozadju skriva SDA. Po podatkih iz literature reaktivno levkopenijo opisujejo pri 2–17 % bolnikov s SDA (<xref ref-type="bibr" rid="b25">25</xref>,<xref ref-type="bibr" rid="b26">26</xref>). Običajno je blaga in vrednosti niso manjše od 3,0 × 10<sup>9</sup> /L (<xref ref-type="bibr" rid="b22">22</xref>). V naši analizi smo levkopenijo zabeležili pri 7 % bolnikov. V podobnem deležu smo beležili tudi trombocitopenijo, ki pa je v literaturi redkeje opisana pridružena sprememba v krvni sliki pri SDA (<xref ref-type="bibr" rid="b27">27</xref>,<xref ref-type="bibr" rid="b28">28</xref>). Pri kombinaciji anemije in trombocitopenije je pomembno pomisliti tudi na trombotično mikroangiopatijo oz. eno njenih oblik, kotsta trombotična trombocitopenična purpura in hemolitični uremični sindrom, ki imata značilno klinično sliko in odstopanja v drugih laboratorijskih izvidih. Zabeležili smo nekaj primerov pancitopenije, vendar je ta pri SDA zelo redka (<xref ref-type="bibr" rid="b29">29</xref>). Znižanje vseh celičnih vrednosti v krvni sliki pogosteje ugotavljamo pri megaloblastni anemiji (<xref ref-type="bibr" rid="b30">30</xref>). Ob nadomeščanju železa tudi opisane pridružene spremembe v krvni sliki običajno izzvenijo. Če SDA izzveni, druga pridružena sprememba v krvni sliki pa ostaja, je potrebna nadaljnja hematološka obravnava, saj se v ozadju lahko skriva pridružena krvna bolezen (<xref ref-type="bibr" rid="b22">22</xref>).</p>
         <p>Na kontrolni pregled je bilo naročenih presenetljivo veliko število bolnikov. Menimo, da v večini primerov za to ni pravega razloga in da spremljanje bolnika s SDA sodi v pristojnost izbranega družinskega zdravnika.</p>
         <p>Pred prvim pregledom v ambulanti KOH je več kot polovica napotenih bolnikov prejemala pripravke železa. SDA vedno zdravimo z železom.</p>
         <p>Oralno železo je prva izbira pri zdravljenju hemodinamsko stabilnih bolnikov s SDA (<xref ref-type="bibr" rid="b1">1</xref>). Priporočeni dnevni odmerek za odraslega bolnika je 200 mg, ki ga običajno razdelimo na jutranji in večerni odmerek. Zdravimo 3 mesece. Pričakovan porast ravni hemoglobina je 20 g/L v 3 tednih oz. 1 g/L dnevno (<xref ref-type="bibr" rid="b20">20</xref>,<xref ref-type="bibr" rid="b31">31</xref>). Za zapolnitev zalog železa nadaljujemo z zdravljenjem z odmerkom 100 mg na dan še 3–6 mesecev (<xref ref-type="bibr" rid="b32">32</xref>). Absorpcija železa je boljša, če se železo jemlje na tešče ali vsaj dve uri po obroku ter ob dodatku vitamina C (<xref ref-type="bibr" rid="b1">1</xref>). Nekateri avtorji svetujejo jemanje pripravkov železa ob mesnem obroku (<xref ref-type="bibr" rid="b11">11</xref>). Absorpcija se zmanjša ob sočasnim uživanjem kalcija (mleko in mlečni izdelki), čreslovine (črni čaj, nekateri zeliščni čaji, rdeče vino), fitatov (kosmiči, žitarice) in kofeina (<xref ref-type="bibr" rid="b33">33</xref>).</p>
         <p>Železovi pripravki lahko povzročajo prebavne težave, kar je najpogostejši razlog za neučinkovito zdravljenje (<xref ref-type="bibr" rid="b11">11</xref>). Redno uživanje železovih pripravkov je namreč za učinkovitost zdravljenja pomembnejše od izbire med dvovalentno ali trivalentno obliko železa (<xref ref-type="bibr" rid="b1">1</xref>). Nekateri proizvajalci menijo, da so pripravki s počasnim sproščanjem železa (<italic toggle="yes">angl.</italic> slow release) ustreznejši. Vendar se prične železo iz tovrstnega pripravka sproščati šele distalno od dvanajstnika, kjer absorbcije ni več (<xref ref-type="bibr" rid="b1">1</xref>). Večina železa se namreč absorbira v zgornjih delih prebavil do polovice jejunuma. Stranski učinki so tako še bolj izraziti. Uživanje železovih pripravkov obarva blato črno, vendar je test za prisotnost krvi v blatu negativen (<xref ref-type="bibr" rid="b1">1</xref>).</p>
         <p>Razumevanje vloge hepcidina je spremenilo pogled na zdravljenje z oralnim železom. Novejše raziskave kažejo, da enkratni dnevni odmerek železa poveča vrednost hepcidina v krvi, ta pa moti absorpcijo naslednjih dnevnih odmerkov oralnega železa. Učinek hepcidina lahko traja do 48 ur (<xref ref-type="bibr" rid="b37">37</xref>). Shema odmerjanja železa v prihodnosti bo morda vključevala samo enkratni dnevni odmerek, predvidoma vsak drug dan (<xref ref-type="bibr" rid="b38">38</xref>).Potrebne bodo še dodatne klinične raziskave, zaenkrat pa se svetuje še standardno odmerjanje oralnih oblik železa, kar smo v prispevku že opisali.</p>
         <p>Če se vrednost hemoglobina po 4–6 tednih zdravljenja z minimalno 100 mg elementarnega železa dnevno ne poviša za 10 g/L, govorimo o trdovratni (refraktarni) anemiji zaradi pomanjkanja železa (<xref ref-type="bibr" rid="b2">2</xref>0). Pogosti razlogi refraktarnosti so celiakija, avtoimunski atrofični gastritis, gastritis zaradi okužbe z bakterijo <italic toggle="yes">H. pylori</italic> in dedna oblika SDA, imenovana IRIDA (<italic toggle="yes">angl.</italic> iron refractory iron deficiency anaemia) (<xref ref-type="bibr" rid="b20">20</xref>). SDA je pri celiakiji najpogostejši zunajčrevesni pojav. Vzrok bolezni je kombinacija motene absorpcije železa in prikritih krvavitev (<xref ref-type="bibr" rid="b20">20</xref>). Pomanjkanje želodčne kisline moti topnost peroralnega železa pri avtoimunskem atrofičnem gastritisu (<xref ref-type="bibr" rid="b20">20</xref>). Klinične raziskave so potrdile povezavo refraktarne oblike SDA z gastritisom zaradi okužbe z bakterijo <italic toggle="yes">H. pylori</italic>. Jasen mehanizem delovanja bakterije na absorpcijo železa ni poznan, verjetno pa gre za kombinacijo kompetitvnega delovanja bakterije za privzem železa, prikritih krvavitev in alkaliziranje želodčne kisline (<xref ref-type="bibr" rid="b20">20</xref>). Sočasno izkoreninjenje bakterije <italic toggle="yes">H. pylori</italic> in nadomeščanje železa sta SDA pri večini bolnikov odpravila (<xref ref-type="bibr" rid="b34">34</xref>). IRIDA je redka dedna motnja, pri kateri je mutiran gen TMPRSS6, ki kodira encim metatriptazo-2 (<xref ref-type="bibr" rid="b1">1</xref>). Ta sodeluje pri uravnavanju izločanja hormona hepcidina. Pri tej bolezni je vrednost hepcidina zelo visoka in moti absorpcijo železa iz prebavil. V laboratorijskih izvidih je ob hipokromni mikrocitni anemiji izvid statusa železa podoben kot pri AKV; vrednost serumskega železa je zelo nizka, serumski feritin pa normalen ali celo visok. Od AKV je ločimo po odsotnosti znakov vnetja. Pogosteje jo odkrijemo pri otrocih in mladih odraslih.</p>
         <table-wrap position="anchor" id="table6" orientation="portrait">
            <label>Tabela 6:</label>
            <caption>
               <p> Pripravki za oralno zdravljenje SDA.</p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <th rowspan="1" colspan="1">Lastniško ime</th>
                     <th rowspan="1" colspan="1">Učinkovina</th>
                     <th rowspan="1" colspan="1">Pakiranje</th>
                     <th rowspan="1" colspan="1">Odmerek *</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td rowspan="1" colspan="1">Ferrum Lek®</td>
                     <td rowspan="1" colspan="1">trivalentni železov oksid</td>
                     <td rowspan="1" colspan="1">30 × 100 mg žvečljive tablete; 100 ml sirupa, 50 mg/5 ml</td>
                     <td rowspan="1" colspan="1">
                        <p>1–3 tbl/dan</p>
                        <p>10–30 ml/dan</p>
                     </td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Eisensulfat Lomapharm®</td>
                     <td rowspan="1" colspan="1">dvovalentni železov sulfat</td>
                     <td rowspan="1" colspan="1">
                        <p>20 x, 50 x, 100 x</p>
                        <p>100 mg tablete</p>
                     </td>
                     <td rowspan="1" colspan="1">1 tbl/12 ur</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Legofer®</td>
                     <td rowspan="1" colspan="1">trivalentni železov proteinsukcinilat</td>
                     <td rowspan="1" colspan="1">
                        <p>150 ml sirupa,</p>
                        <p>40 mg/15 ml</p>
                     </td>
                     <td rowspan="1" colspan="1">7,5–15 ml/12 ur</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Tardyfer®</td>
                     <td rowspan="1" colspan="1">dvovalentni železov sulfat</td>
                     <td rowspan="1" colspan="1">30 × 80 mg tablete</td>
                     <td rowspan="1" colspan="1">1–2 tbl/dan</td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <p>* Odmerek za očitno pomanjkanje železa pri odraslih.</p>
            </table-wrap-foot>
         </table-wrap>
         <p>Indikacije za intravensko zdravljenje z železom so neprenašanje oralnih železovih pripravkov, refraktarna anemija ob pomanjkanju železa, zavračanje transfuzije krvnih pripravkov zaradi verskih razlogov (Jehovove priče), zapolnitev zalog železa pred zdravljenjem z eritropoetinom (<xref ref-type="bibr" rid="b1">1</xref>). Pri intravenskem nadomeščanju serumska raven hemoglobina hitro poraste, zato ga uporabljamo pri bolnikih pred načrtovano operacijo, ki imajo SDA, pri nosečnicah v drugem in tretjem trimesečju, če je anemija huda, ali ob krvavitvi iz prebavil pri bolnikih z motnjami strjevanja krvi. Strah pred alergijskimi reakcijami ob infuziji železa izvira iz preteklosti, ko je bil dekstran nosilec železa v intravenskih pripravkih (<xref ref-type="bibr" rid="b39">39</xref>). Slednji je bil vzrok za večino alergijskih reakcij. Danes so na voljo pripravki brez dekstrana. Alergijske reakcije so redke. Bolnik lahko varno prejme intravensko železo v ambulanti zdravstvenega doma, zato napotitev k hematologu ni upravičena (<xref ref-type="bibr" rid="b4">4</xref>0). Stroške krije Zavod za zdravstveno zavarovanje Slovenije. Pri nosečnicah v prvem trimesečju se zaradi pomanjkanja študij o varnosti dajanja železa v veno izogibamo (<xref ref-type="bibr" rid="b40">40</xref>).</p>
         <p>Transfuzija koncentriranih eritrocitov (KE) je pri SDA na mestu zgolj ob resnih kliničnih težavah in predstavlja simptomatski ukrep (<xref ref-type="bibr" rid="b1">1</xref>). Zdravi posamezniki imajo korist od transfuzije KE pri vrednosti hemoglobina, ki je manjša od 60 g/L. Predvsem srčni bolniki slabše prenašajo anemijo. Tako so večjo umrljivost ugotovili pri srčnih bolnikih z vrednostjo hemoglobina, manjšo od 100 g/L (<xref ref-type="bibr" rid="b41">41</xref>). Transfuzijo KE običajno prejmejo bolniki po akutni krvavitvi, in sicer ne glede na mesto krvavitve, in tisti bolniki z večjo kronično krvavitvijo, pri kateri hematopoeza ne zmore dohajati izgube krvi. To so na primer bolniki s hereditarno hemoragično teleangiektazijo (<xref ref-type="bibr" rid="b1">1</xref>). Transfuzija KE je na mestu pri kroničnih bolnikih s srčnim popuščanjem, kronično ledvično ali jetrno boleznijo in drugimi kroničnimi boleznimi, kjer je prag za nadomeščanje s transfuzijo KE višji oz. odvisen od simptomov in znakov anemije. Transfuzija KE vedno poslabša potek in uspešnost zdravljenja osnovne bolezni.</p>
         <p>Ob prejetih transfuzijah KE morajo bolniki hkrati pričeti z nadomeščanjem železa, praviloma v intravenski obliki (<xref ref-type="bibr" rid="b42">42</xref>). Eritropoetini pri zdravljenju SDA niso na mestu.</p>
         <p>Zdravila za zdravljenje anemije zaradi pomanjkanja železa v Sloveniji (<xref ref-type="bibr" rid="b43">43</xref>):</p>
         <list>
            <list-item>
               <label>•</label>
               <p>Zdravila za peroralno uporabo so navedena v <xref ref-type="table" rid="table6">Tabeli 6</xref>.</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>Zdravila za intravensko uporabo so navedena v <xref ref-type="table" rid="table7">Tabeli 7</xref>.</p>
            </list-item>
         </list>
         <table-wrap position="anchor" id="table7" orientation="portrait">
            <label>Tabela 7:</label>
            <caption>
               <p> Pripravki za intravensko zdravljenje SDA.</p>
            </caption>
            <table>
               <colgroup span="1">
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
                  <col span="1"/>
               </colgroup>
               <thead>
                  <tr>
                     <th rowspan="1" colspan="1">Lastniško ime</th>
                     <th rowspan="1" colspan="1">Učinkovina in nosilec</th>
                     <th rowspan="1" colspan="1">Pakiranje</th>
                     <th rowspan="1" colspan="1">Odmerek*</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td rowspan="1" colspan="1">Ferrologic®</td>
                     <td rowspan="1" colspan="1">trivalentni železov oksid saharat</td>
                     <td rowspan="1" colspan="1">
                        <p>20 mg/ml</p>
                        <p>5 ml ampule</p>
                     </td>
                     <td rowspan="1" colspan="1">100–200 mg/dan do 3-krat na teden ali največ 500 mg 1-krat na teden</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Iroprem®</td>
                     <td rowspan="1" colspan="1">trivalentna železova karboksimaltoza</td>
                     <td rowspan="1" colspan="1">
                        <p>50 mg/ml</p>
                        <p>10 ml viale</p>
                        <p>2 ml viale</p>
                     </td>
                     <td rowspan="1" colspan="1">največ 1000 mg/dan 1-krat na teden</td>
                  </tr>
                  <tr>
                     <td rowspan="1" colspan="1">Venofer®</td>
                     <td rowspan="1" colspan="1">trivalentni železov oksid saharat</td>
                     <td rowspan="1" colspan="1">
                        <p>20 mg/ml</p>
                        <p>5 ml ampule</p>
                     </td>
                     <td rowspan="1" colspan="1">100–200 mg/dan do 3-krat na teden ali največ 500 mg 1-krat na teden</td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <p>*Celotni kumulativni odmerek intravenskega železa izračunamo:</p>
               <p>Ferrologic® in Venofer®</p>
               <p>Celotna količina železa, ki naj jo bolnik prejme [mg] = telesna masa [kg] x (želena koncentracija Hb – dejanska koncentracija Hb) [g/l] × 0,24* + količina železa za zapolnitev zalog [500 mg]</p>
               <p>Iroprem®</p>
               <p>Bolniki s telesno maso 35 kg do &lt; 70 kg; Hb &lt; 10 g/dl: 1.500 mg, Hb ≥ 10 g/dl: 1.000 mg</p>
               <p>Bolniki s telesno maso ≥ 70 kg; Hb &lt; 10 g/dl: 2.000 mg, Hb ≥ 10 g/dl: 1.500 mg</p>
            </table-wrap-foot>
         </table-wrap>
      </sec>
      <sec id="s5" sec-type="Zaključek">
         <label>5</label>
         <title>Zaključek</title>
         <p>Anemija zaradi pomanjkanja železa je pogost vzrok napotitve bolnikov v hematološko ambulanto. V naši raziskavi so bile najpogosteje obravnavane ženske v rodni dobi. V hematološki ambulanti je večina bolnikov s SDA prejela intravensko železo. Podatki kažejo, da je mikrocitna anemija slabo prepoznano stanje. V hematološko ambulanto napotimo bolnike s hudo mikrocitno anemijo s simptomi (Hb, manjši od 70 g/L) ter tiste, pri katerih kljub nadomeščanju s pripravki železa in porastu vrednosti hemoglobina, opažamo vztrajanje pridruženih sprememb v krvni sliki.</p>
      </sec>
   </body>
   <back>
      <ref-list>
         <ref id="b1">
            <label>1. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Camaschella</surname>
                     <given-names>C</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Iron-deficiency anemia</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2015</year>
                    <month>May</month>;
                    <volume>372</volume>(
                    <issue>19</issue>):
                    <fpage>1832</fpage>–
                    <lpage>43</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMra1401038</pub-id>
                    <pub-id pub-id-type="pmid">25946282</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
         </ref>
         <ref id="b2">
            <label>2. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Short</surname>
                     <given-names>MW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Domagalski</surname>
                     <given-names>JE</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Iron deficiency anemia: evaluation and management</article-title>. 
                    <source>Am Fam Physician</source>. 
                    <year>2013</year>
                    <month>Jan</month>;
                    <volume>87</volume>(
                    <issue>2</issue>):
                    <fpage>98</fpage>–
                    <lpage>104</lpage>.
                    <pub-id pub-id-type="pmid">23317073</pub-id>
                    <issn>1532-0650</issn>
                </mixed-citation>
         </ref>
         <ref id="b3">
            <label>3. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Nishimura</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Matsuzaki</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fujimoto</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kawakita</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Takatsuki</surname>
                     <given-names>K</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Münchhausen syndrome with severe iron deficiency anemia</article-title>. 
                    <source>Rinsho Ketsueki</source>. 
                    <year>1992</year>
                    <month>Apr</month>;
                    <volume>33</volume>(
                    <issue>4</issue>):
                    <fpage>478</fpage>–
                    <lpage>82</lpage>.
                    <pub-id pub-id-type="pmid">1602612</pub-id>
                    <issn>0485-1439</issn>
                </mixed-citation>
         </ref>
         <ref id="b4">
            <label>4. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Khadem</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Scott</surname>
                     <given-names>IA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Klein</surname>
                     <given-names>K</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Evaluation of iron deficiency anaemia in tertiary hospital settings: room for improvement?</article-title>
                    <source>Intern Med J</source>. 
                    <year>2012</year>
                    <month>Jun</month>;
                    <volume>42</volume>(
                    <issue>6</issue>):
                    <fpage>658</fpage>–
                    <lpage>64</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1445-5994.2012.02724.x</pub-id>
                    <pub-id pub-id-type="pmid">22288902</pub-id>
                    <issn>1444-0903</issn>
                </mixed-citation>
         </ref>
         <ref id="b5">
            <label>5. </label>
            <mixed-citation publication-type="webpage">
                    <person-group person-group-type="author">
                        <collab>World Health Organ</collab>
                    </person-group>. 
                    <source>Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity</source>.
                    <publisher-loc>Geneva</publisher-loc>:
                    <publisher-name>WHO</publisher-name>;
                    <year>2011</year>. 
                    [<date-in-citation content-type="access-date" iso-8601-date="2017-01-10">cited 2017 Jan 10</date-in-citation>]. 
                    <comment>Available from:<uri>http://www.who.int/vmnis/indicators/haemoglobin.pdf</uri>
               </comment>.
                </mixed-citation>
         </ref>
         <ref id="b6">
            <label>6. </label>
            <mixed-citation publication-type="webpage">
                    <person-group>
                  <name name-style="western">
                     <surname/>
                  </name>
               </person-group>.
                    <source>Laboratorijski vodnik UKC Ljubljana, INTKOHem- Interna klinika - KO za hematologijo-Specializirani hematološki laboratorij</source>. 
                    [<date-in-citation content-type="access-date" iso-8601-date="2017-01-10">cited 2017 Jan 10</date-in-citation>]. 
                    <comment>Available from:<uri>http://lab.biarti.si/</uri>
               </comment>.
                </mixed-citation>
         </ref>
         <ref id="b7">
            <label>7. </label>
            <mixed-citation publication-type="webpage">
                <person-group>
                  <name name-style="western">
                     <surname/>
                  </name>
               </person-group>.
                <source>Laboratorijski vodnik UKC Ljubljana, KIKKB Klinični inštitut za klinično kemijo in biokemijo</source>. 
                [<date-in-citation content-type="access-date" iso-8601-date="2017-01-10">cited 2017 Jan 10</date-in-citation>].
                </mixed-citation>
         </ref>
         <ref id="b8">
            <label>8. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Alleyne</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Horne</surname>
                     <given-names>MK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Miller</surname>
                     <given-names>JL</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Individualized treatment for iron-deficiency anemia in adults</article-title>. 
                    <source>Am J Med</source>. 
                    <year>2008</year>
                    <month>Nov</month>;
                    <volume>121</volume>(
                    <issue>11</issue>):
                    <fpage>943</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.amjmed.2008.07.012</pub-id>
                    <pub-id pub-id-type="pmid">18954837</pub-id>
                    <issn>0002-9343</issn>
                </mixed-citation>
         </ref>
         <ref id="b9">
            <label>9. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Mills</surname>
                     <given-names>HL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Abdel-Baki</surname>
                     <given-names>MS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Teruya</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dietrich</surname>
                     <given-names>JE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Shah</surname>
                     <given-names>MD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mahoney</surname>
                     <given-names>D</given-names>
                     <suffix>Jr</suffix>
                  </name>
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Platelet function defects in adolescents with heavy menstrual bleeding</article-title>. 
                    <source>Haemophilia</source>. 
                    <year>2014</year>
                    <month>Mar</month>;
                    <volume>20</volume>(
                    <issue>2</issue>):
                    <fpage>249</fpage>–
                    <lpage>54</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/hae.12293</pub-id>
                    <pub-id pub-id-type="pmid">24251971</pub-id>
                    <issn>1351-8216</issn>
                </mixed-citation>
         </ref>
         <ref id="b10">
            <label>10. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Dilley</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Drews</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Miller</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lally</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Austin</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ramaswamy</surname>
                     <given-names>D</given-names>
                  </name>
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia</article-title>. 
                    <source>Obstet Gynecol</source>. 
                    <year>2001</year>
                    <month>Apr</month>;
                    <volume>97</volume>(
                    <issue>4</issue>):
                    <fpage>630</fpage>–
                    <lpage>6</lpage>.
                    <pub-id pub-id-type="pmid">11275041</pub-id>
                    <issn>0029-7844</issn>
                </mixed-citation>
         </ref>
         <ref id="b11">
            <label>11. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>DeLoughery</surname>
                     <given-names>TG</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Microcytic anemia</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2014</year>
                    <month>Oct</month>;
                    <volume>371</volume>(
                    <issue>14</issue>):
                    <fpage>1324</fpage>–
                    <lpage>31</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMra1215361</pub-id>
                    <pub-id pub-id-type="pmid">25271605</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
         </ref>
         <ref id="b12">
            <label>12. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Johnson-Wimbley</surname>
                     <given-names>TD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Graham</surname>
                     <given-names>DY</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Diagnosis and management of iron deficiency anemia in the 21st century</article-title>. 
                    <source>Therap Adv Gastroenterol</source>. 
                    <year>2011</year>
                    <month>May</month>;
                    <volume>4</volume>(
                    <issue>3</issue>):
                    <fpage>177</fpage>–
                    <lpage>84</lpage>. 
                    <pub-id pub-id-type="doi">10.1177/1756283X11398736</pub-id>
                    <pub-id pub-id-type="pmid">21694802</pub-id>
                    <issn>1756-283X</issn>
                </mixed-citation>
         </ref>
         <ref id="b13">
            <label>13. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Bermejo</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>García-López</surname>
                     <given-names>S</given-names>
                  </name>
                    </person-group>. 
                    <article-title>A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases</article-title>. 
                    <source>World J Gastroenterol</source>. 
                    <year>2009</year>
                    <month>Oct</month>;
                    <volume>15</volume>(
                    <issue>37</issue>):
                    <fpage>4638</fpage>–
                    <lpage>43</lpage>. 
                    <pub-id pub-id-type="doi">10.3748/wjg.15.4638</pub-id>
                    <pub-id pub-id-type="pmid">19787826</pub-id>
                    <issn>1007-9327</issn>
                </mixed-citation>
         </ref>
         <ref id="b14">
            <label>14. </label>
            <mixed-citation publication-type="webpage">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Todorova</surname>
                     <given-names>B</given-names>
                  </name>
                    </person-group>. 
                    <source>Talasemije v Sloveniji</source>.
                    <year>2014</year>. 
                    [<date-in-citation content-type="access-date" iso-8601-date="2017-01-10">cited 2017 Jan 10</date-in-citation>]. 
                    <comment>Available from:<uri>http://www.hematologija.org/admin/files/news/pics/file/Todorova%20B%20p2014.pdf</uri>
               </comment>.
                </mixed-citation>
         </ref>
         <ref id="b15">
            <label>15. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Nuchprayoon</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sukthawee</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nuchprayoon</surname>
                     <given-names>T</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Red cell indices and therapeutic trial of iron in diagnostic work-up for anemic Thai females</article-title>. 
                    <source>J Med Assoc Thai</source>. 
                    <year>2003</year>
                    <month>Jun</month>;
                    <volume>86</volume>
                    <supplement>Suppl 2</supplement>:
                    <fpage>S160</fpage>–
                    <lpage>9</lpage>.
                    <pub-id pub-id-type="pmid">12929984</pub-id>
                    <issn>0125-2208</issn>
                </mixed-citation>
         </ref>
         <ref id="b16">
            <label>16. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Körber</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wölfler</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Neubauer</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Robier</surname>
                     <given-names>C</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Short Communication Red blood cell morphology in patients with β-thalassemia minor</article-title>. 
                    <source>J Lab Med</source>.
                    <year>2016</year>;
                    <volume>41</volume>(
                    <issue>1</issue>):
                    <fpage>49</fpage>–
                    <lpage>52</lpage>.
                    <pub-id pub-id-type="doi">10.1515/labmed-2016-0052</pub-id>
                    <issn>2567-9430 </issn>  
                </mixed-citation>
         </ref>
         <ref id="b17">
            <label>17. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ganz</surname>
                     <given-names>T</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Hepcidin and iron regulation, 10 years later</article-title>. 
                    <source>Blood</source>. 
                    <year>2011</year>
                    <month>Apr</month>;
                    <volume>117</volume>(
                    <issue>17</issue>):
                    <fpage>4425</fpage>–
                    <lpage>33</lpage>. 
                    <pub-id pub-id-type="doi">10.1182/blood-2011-01-258467</pub-id>
                    <pub-id pub-id-type="pmid">21346250</pub-id>
                    <issn>0006-4971</issn>
                </mixed-citation>
         </ref>
         <ref id="b18">
            <label>18. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Locatelli</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Aljama</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bárány</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Canaud</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Carrera</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Eckardt</surname>
                     <given-names>KU</given-names>
                  </name>
                        <etal>et al</etal>; 
                        <collab>European Best Practice Guidelines Working Group</collab>
                    </person-group>. 
                    <article-title>Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure</article-title>. 
                    <source>Nephrol Dial Transplant</source>. 
                    <year>2004</year>
                    <month>May</month>;
                    <volume>19</volume>
                    <supplement>Suppl 2</supplement>:
                    <fpage>ii1</fpage>–
                    <lpage>47</lpage>.
                    <pub-id pub-id-type="pmid">15206425</pub-id>
                    <issn>0931-0509</issn>
                </mixed-citation>
         </ref>
         <ref id="b19">
            <label>19. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Thomas</surname>
                     <given-names>DW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hinchliffe</surname>
                     <given-names>RF</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Briggs</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Macdougall</surname>
                     <given-names>IC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Littlewood</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cavill</surname>
                     <given-names>I</given-names>
                  </name>; 
                        <collab>British Committee for Standards in Haematology</collab>
                    </person-group>. 
                    <article-title>Guideline for the laboratory diagnosis of functional iron deficiency</article-title>. 
                    <source>Br J Haematol</source>. 
                    <year>2013</year>
                    <month>Jun</month>;
                    <volume>161</volume>(
                    <issue>5</issue>):
                    <fpage>639</fpage>–
                    <lpage>48</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/bjh.12311</pub-id>
                    <pub-id pub-id-type="pmid">23573815</pub-id>
                    <issn>0007-1048</issn>
                </mixed-citation>
         </ref>
         <ref id="b20">
            <label>20. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hershko</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Camaschella</surname>
                     <given-names>C</given-names>
                  </name>
                    </person-group>. 
                    <article-title>How I treat unexplained refractory iron deficiency anemia</article-title>. 
                    <source>Blood</source>. 
                    <year>2014</year>
                    <month>Jan</month>;
                    <volume>123</volume>(
                    <issue>3</issue>):
                    <fpage>326</fpage>–
                    <lpage>33</lpage>. 
                    <pub-id pub-id-type="doi">10.1182/blood-2013-10-512624</pub-id>
                    <pub-id pub-id-type="pmid">24215034</pub-id>
                    <issn>0006-4971</issn>
                </mixed-citation>
         </ref>
         <ref id="b21">
            <label>21. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Sinniah</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Doggart</surname>
                     <given-names>JR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Neill</surname>
                     <given-names>DW</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Diurnal variations of the serum iron in normal subjects and in patients with haemochromatosis</article-title>. 
                    <source>Br J Haematol</source>. 
                    <year>1969</year>
                    <month>Oct</month>;
                    <volume>17</volume>(
                    <issue>4</issue>):
                    <fpage>351</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1365-2141.1969.tb01381.x</pub-id>
                    <pub-id pub-id-type="pmid">5346408</pub-id>
                    <issn>0007-1048</issn>
                </mixed-citation>
         </ref>
         <ref id="b22">
            <label>22. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Skopec</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zver</surname>
                     <given-names>S</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Reaktivne spremembe krvne slike in osnove zdravljenja anemije zaradi pomanjkanja železa</article-title>. 
                    <source>Zdrav Vestn</source>. 
                    <year>2008</year>;
                    <volume>77</volume>(
                    <issue>1</issue>):
                    <fpage>161</fpage>–
                    <lpage>5</lpage>.
                    <issn>0350-0063</issn>
                </mixed-citation>
         </ref>
         <ref id="b23">
            <label>23. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Akan</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Güven</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Aydogdu</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Arat</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Beksaç</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dalva</surname>
                     <given-names>K</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Thrombopoietic cytokines in patients with iron deficiency anemia with or without thrombocytosis</article-title>. 
                    <source>Acta Haematol</source>. 
                    <year>2000</year>;
                    <volume>103</volume>(
                    <issue>3</issue>):
                    <fpage>152</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.1159/000041038</pub-id>
                    <pub-id pub-id-type="pmid">10940653</pub-id>
                    <issn>0001-5792</issn>
                </mixed-citation>
         </ref>
         <ref id="b24">
            <label>24. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Bleeker</surname>
                     <given-names>JS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hogan</surname>
                     <given-names>WJ</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies</article-title>. 
                    <source>Thrombosis</source>. 
                    <year>2011</year>;
                    <volume>2011</volume>:
                    <fpage>536062</fpage>. 
                    <pub-id pub-id-type="doi">10.1155/2011/536062</pub-id>
                    <pub-id pub-id-type="pmid">22084665</pub-id>
                    <issn>2090-1488</issn>
                </mixed-citation>
         </ref>
         <ref id="b25">
            <label>25. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lim</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lee</surname>
                     <given-names>EY</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Choi</surname>
                     <given-names>IS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kim</surname>
                     <given-names>TY</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yoon</surname>
                     <given-names>SS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kim</surname>
                     <given-names>KH</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Leukopenia in patients with iron deficiency anemia</article-title>. 
                    <source>Blood</source>. 
                    <year>2011</year>;
                    <volume>118</volume>(
                    <issue>21</issue>):
                    <fpage>5279</fpage>.
                    <issn>0006-4971</issn>
                </mixed-citation>
         </ref>
         <ref id="b26">
            <label>26. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lima</surname>
                     <given-names>CS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Paula</surname>
                     <given-names>EV</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Takahashi</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Saad</surname>
                     <given-names>ST</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lorand-Metze</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Costa</surname>
                     <given-names>FF</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Causes of incidental neutropenia in adulthood</article-title>. 
                    <source>Ann Hematol</source>. 
                    <year>2006</year>
                    <month>Oct</month>;
                    <volume>85</volume>(
                    <issue>10</issue>):
                    <fpage>705</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s00277-006-0150-0</pub-id>
                    <pub-id pub-id-type="pmid">16807747</pub-id>
                    <issn>0939-5555</issn>
                </mixed-citation>
         </ref>
         <ref id="b27">
            <label>27. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lopas</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rabiner</surname>
                     <given-names>SF</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Thrombocytopenia associated with iron deficiency anemia. A report of five cases</article-title>. 
                    <source>Clin Pediatr (Phila)</source>. 
                    <year>1966</year>
                    <month>Oct</month>;
                    <volume>5</volume>(
                    <issue>10</issue>):
                    <fpage>609</fpage>–
                    <lpage>16</lpage>. 
                    <pub-id pub-id-type="doi">10.1177/000992286600501008</pub-id>
                    <pub-id pub-id-type="pmid">5926915</pub-id>
                    <issn>0009-9228</issn>
                </mixed-citation>
         </ref>
         <ref id="b28">
            <label>28. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Morris</surname>
                     <given-names>VK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Spraker</surname>
                     <given-names>HL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Howard</surname>
                     <given-names>SC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ware</surname>
                     <given-names>RE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Reiss</surname>
                     <given-names>UM</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Severe thrombocytopenia with iron deficiency anemia</article-title>. 
                    <source>Pediatr Hematol Oncol</source>. 
                    <year>2010</year>
                    <month>Aug</month>;
                    <volume>27</volume>(
                    <issue>5</issue>):
                    <fpage>413</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.3109/08880011003739455</pub-id>
                    <pub-id pub-id-type="pmid">20670168</pub-id>
                    <issn>0888-0018</issn>
                </mixed-citation>
         </ref>
         <ref id="b29">
            <label>29. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ganti</surname>
                     <given-names>AK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Shonka</surname>
                     <given-names>NA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Haire</surname>
                     <given-names>WD</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Pancytopenia due to iron deficiency worsened by iron infusion: a case report</article-title>. 
                    <source>J Med Case Reports</source>. 
                    <year>2007</year>
                    <month>Dec</month>;
                    <volume>1</volume>(
                    <issue>1</issue>):
                    <fpage>175</fpage>. 
                    <pub-id pub-id-type="doi">10.1186/1752-1947-1-175</pub-id>
                    <pub-id pub-id-type="pmid">18067664</pub-id>
                    <issn>1752-1947</issn>
                </mixed-citation>
         </ref>
         <ref id="b30">
            <label>30. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Das Makheja</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kumar Maheshwari</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Arain</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kumar</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kumari</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vikash</surname>
                  </name>
                    </person-group>. 
                    <article-title>The common causes leading to pancytopenia in patients presenting to tertiary care hospital</article-title>. 
                    <source>Pak J Med Sci</source>. 
                    <year>2013</year>
                    <month>Sep</month>;
                    <volume>29</volume>(
                    <issue>5</issue>):
                    <fpage>1108</fpage>–
                    <lpage>11</lpage>.
                    <pub-id pub-id-type="pmid">24353701</pub-id>
                    <issn>1682-024X</issn>
                </mixed-citation>
         </ref>
         <ref id="b31">
            <label>31. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Andrews</surname>
                     <given-names>NC</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Iron metabolism: iron deficiency and iron overload</article-title>. 
                    <source>Annu Rev Genomics Hum Genet</source>. 
                    <year>2000</year>;
                    <volume>1</volume>(
                    <issue>1</issue>):
                    <fpage>75</fpage>–
                    <lpage>98</lpage>. 
                    <pub-id pub-id-type="doi">10.1146/annurev.genom.1.1.75</pub-id>
                    <pub-id pub-id-type="pmid">11701625</pub-id>
                    <issn>1527-8204</issn>
                </mixed-citation>
         </ref>
         <ref id="b32">
            <label>32. </label>
            <mixed-citation publication-type="book-chapter">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Andoljšek</surname>
                     <given-names>D</given-names>
                  </name>
                    </person-group>
                    <chapter-title>Bolezni krvi in krvotvornih organov</chapter-title>. In:
                    <person-group person-group-type="author">
                    <name name-style="western">
                     <surname>Kocijančič</surname>
                     <given-names>A</given-names>
                  </name>,
                     <name name-style="western">
                     <surname>Mrelje</surname>
                     <given-names>V</given-names>
                  </name>, 
                    <name name-style="western">
                     <surname>Štajer</surname>
                     <given-names>D</given-names>
                  </name>,
                        <name name-style="western">
                     <surname>černelč</surname>
                     <given-names>P</given-names>
                  </name>, 
                    <role>eds</role>
                    </person-group>. 
                    <source>Interna medicina</source>. 
                    <edition>3rd ed</edition>.
                    <publisher-loc>Ljubljana</publisher-loc>:
                    <publisher-name>Littera picta</publisher-name>;
                    <year>2011</year>.pp. 
                    <fpage>1243</fpage>–
                    <lpage>393</lpage>.
                </mixed-citation>
         </ref>
         <ref id="b33">
            <label>33. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Zijp</surname>
                     <given-names>IM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Korver</surname>
                     <given-names>O</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tijburg</surname>
                     <given-names>LB</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Effect of tea and other dietary factors on iron absorption</article-title>. 
                    <source>Crit Rev Food Sci Nutr</source>. 
                    <year>2000</year>
                    <month>Sep</month>;
                    <volume>40</volume>(
                    <issue>5</issue>):
                    <fpage>371</fpage>–
                    <lpage>98</lpage>. 
                    <pub-id pub-id-type="doi">10.1080/10408690091189194</pub-id>
                    <pub-id pub-id-type="pmid">11029010</pub-id>
                    <issn>1040-8398</issn>
                </mixed-citation>
         </ref>
         <ref id="b34">
            <label>34. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Marignani</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Angeletti</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bordi</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Malagnino</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mancino</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Delle Fave</surname>
                     <given-names>G</given-names>
                  </name>
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Reversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection</article-title>. 
                    <source>Scand J Gastroenterol</source>. 
                    <year>1997</year>
                    <month>Jun</month>;
                    <volume>32</volume>(
                    <issue>6</issue>):
                    <fpage>617</fpage>–
                    <lpage>22</lpage>. 
                    <pub-id pub-id-type="doi">10.3109/00365529709025109</pub-id>
                    <pub-id pub-id-type="pmid">9200297</pub-id>
                    <issn>0036-5521</issn>
                </mixed-citation>
         </ref>
         <ref id="b35">
            <label>35. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Nairz</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Schroll</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sonnweber</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Weiss</surname>
                     <given-names>G</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The struggle for iron - a metal at the host-pathogen interface</article-title>. 
                    <source>Cell Microbiol</source>. 
                    <year>2010</year>
                    <month>Dec</month>;
                    <volume>12</volume>(
                    <issue>12</issue>):
                    <fpage>1691</fpage>–
                    <lpage>702</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1462-5822.2010.01529.x</pub-id>
                    <pub-id pub-id-type="pmid">20964797</pub-id>
                    <issn>1462-5814</issn>
                </mixed-citation>
         </ref>
         <ref id="b36">
            <label>36. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Zager</surname>
                     <given-names>RA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Johnson</surname>
                     <given-names>AC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hanson</surname>
                     <given-names>SY</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Parenteral iron therapy exacerbates experimental sepsis</article-title>. 
                    <source>Kidney Int</source>. 
                    <year>2004</year>
                    <month>Jun</month>;
                    <volume>65</volume>(
                    <issue>6</issue>):
                    <fpage>2108</fpage>–
                    <lpage>12</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00742.x</pub-id>
                    <pub-id pub-id-type="pmid">15149323</pub-id>
                    <issn>0085-2538</issn>
                </mixed-citation>
         </ref>
         <ref id="b37">
            <label>37. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Moretti</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Goede</surname>
                     <given-names>JS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zeder</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jiskra</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chatzinakou</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tjalsma</surname>
                     <given-names>H</given-names>
                  </name>
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women</article-title>. 
                    <source>Blood</source>. 
                    <year>2015</year>
                    <month>Oct</month>;
                    <volume>126</volume>(
                    <issue>17</issue>):
                    <fpage>1981</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1182/blood-2015-05-642223</pub-id>
                    <pub-id pub-id-type="pmid">26289639</pub-id>
                    <issn>0006-4971</issn>
                </mixed-citation>
         </ref>
         <ref id="b38">
            <label>38. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Schrier</surname>
                     <given-names>SL</given-names>
                  </name>
                    </person-group>. 
                    <article-title>So you know how to treat iron deficiency anemia</article-title>. 
                    <source>Blood</source>. 
                    <year>2015</year>
                    <month>Oct</month>;
                    <volume>126</volume>(
                    <issue>17</issue>):
                    <fpage>1971</fpage>. 
                    <pub-id pub-id-type="doi">10.1182/blood-2015-09-666511</pub-id>
                    <pub-id pub-id-type="pmid">26494915</pub-id>
                    <issn>0006-4971</issn>
                </mixed-citation>
         </ref>
         <ref id="b39">
            <label>39. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Bircher</surname>
                     <given-names>AJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Auerbach</surname>
                     <given-names>M</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Hypersensitivity from intravenous iron products</article-title>. 
                    <source>Immunol Allergy Clin North Am</source>. 
                    <year>2014</year>
                    <month>Aug</month>;
                    <volume>34</volume>(
                    <issue>3</issue>):
                    <fpage>707</fpage>–
                    <lpage>23</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.iac.2014.04.013</pub-id>
                    <pub-id pub-id-type="pmid">25017687</pub-id>
                    <issn>0889-8561</issn>
                </mixed-citation>
         </ref>
         <ref id="b40">
            <label>40. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Rampton</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Folkersen</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fishbane</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hedenus</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Howaldt</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Locatelli</surname>
                     <given-names>F</given-names>
                  </name>
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management</article-title>. 
                    <source>Haematologica</source>. 
                    <year>2014</year>
                    <month>Nov</month>;
                    <volume>99</volume>(
                    <issue>11</issue>):
                    <fpage>1671</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.3324/haematol.2014.111492</pub-id>
                    <pub-id pub-id-type="pmid">25420283</pub-id>
                    <issn>0390-6078</issn>
                </mixed-citation>
         </ref>
         <ref id="b41">
            <label>41. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Carson</surname>
                     <given-names>JL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Strair</surname>
                     <given-names>R</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Transfusion strategies in hematologic and nonhematologic disease</article-title>. 
                    <source>Hematology (Am Soc Hematol Educ Program)</source>. 
                    <year>2014</year>
                    <month>Dec</month>;
                    <volume>2014</volume>(
                    <issue>1</issue>):
                    <fpage>548</fpage>–
                    <lpage>52</lpage>. 
                    <pub-id pub-id-type="doi">10.1182/asheducation-2014.1.548</pub-id>
                    <pub-id pub-id-type="pmid">25696909</pub-id>
                    <issn>1520-4391</issn>
                </mixed-citation>
         </ref>
         <ref id="b42">
            <label>42. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Goddard</surname>
                     <given-names>AF</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>James</surname>
                     <given-names>MW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>McIntyre</surname>
                     <given-names>AS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Scott</surname>
                     <given-names>BB</given-names>
                  </name>; 
                        <collab>British Society of Gastroenterology</collab>
                    </person-group>. 
                    <article-title>Guidelines for the management of iron deficiency anaemia</article-title>. 
                    <source>Gut</source>. 
                    <year>2011</year>
                    <month>Oct</month>;
                    <volume>60</volume>(
                    <issue>10</issue>):
                    <fpage>1309</fpage>–
                    <lpage>16</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/gut.2010.228874</pub-id>
                    <pub-id pub-id-type="pmid">21561874</pub-id>
                    <issn>0017-5749</issn>
                </mixed-citation>
         </ref>
         <ref id="b43">
            <label>43. </label>
            <mixed-citation publication-type="webpage">
                    <source>Centralna baza zdravil 2</source>.
                    [<date-in-citation content-type="access-date" iso-8601-date="2017-01-11">cited 2017 Jan 11</date-in-citation>]. 
                    <comment>Available from:<uri>http://www.cbz.si/cbz/bazazdr2.nsf/Search?SearchView&amp;Query=(%5BSEZNAMUCINKNAZIV%5D=_%C5%BEelezo*)&amp;SearchOrder=4&amp;SearchMax=301</uri>
               </comment>.
                </mixed-citation>
         </ref>
      </ref-list>
   </back>
   <sub-article id="article-en" xml:lang="en" article-type="other">
      <front-stub>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Cardiovascular system</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Original scientific article</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="en">
               <subject>Cardiovascular system</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="en"/>
            <alt-title alt-title-type="running-head" xml:lang="en">Survey of patients with iron deficiency anemia</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Cvejić Vidali</surname>
                  <given-names>Gaja</given-names>
               </name>
               <xref ref-type="aff" rid="en-aff1">1</xref>
               <xref ref-type="corresp" rid="en-corr"/>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Zver</surname>
                  <given-names>Samo</given-names>
               </name>
               <xref ref-type="aff" rid="en-aff1">1</xref>
            </contrib>
         </contrib-group>
         <aff id="en-aff1" xml:lang="en">
            <label>1</label>
            <institution>Department of Haematology, Division of Internal Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
         </aff>
         <abstract xml:lang="en">
            <title>Abstract</title>
            <p>Background: Iron deficiency anaemia (IDA) is the most prevalent type of anaemia and a common cause for patient referrals to the haematology outpatient clinic. The aim of this study was to determine the number of patients with IDA treated at the Haematology Outpatient Clinic of the UMC Ljubljana in the period of two years, as well as to inquire into the causes for their referrals to the clinic, patient characteristics, their complete blood count results at initial examination, the prescribed therapy, the number and the causes of their follow-up visits. We draw special attention to the IDA onset mechanism, the microcytic anaemia therapy principles and the indications prompting a referral of an IDA patient to the haematology specialist.</p>
            <p>Methods: We undertook a retrospective analysis of the medical records of patients who were referred to the Haematology outpatient clinic of the UMC Ljubljana for examination in the two-year period between 1 January 2014 and 31 December 2015 and had been diagnosed with IDA on the basis of their clinical picture and their CBC values. Data were collected with the Hipokrat IT system and statistically evaluated with Microsoft Excel.</p>
            <p>Results: In the period relevant for our research, 277 patients of those who were referred to the Haematology outpatient clinic for medical examination were diagnosed with IDA. 11.6 % of these patients were male and 88.4 % female; 62.1 % of the female patients were of childbearing age. IDA was specified as the referral diagnosis in the cases of no more than 39 % of the patients referred to the specialist outpatient clinic, whilst the medical condition of the remaining percentage of patients was not identified by the referring doctor. Comorbidities were observed in 50.2 % of the patients, and for 62.5 % of the patients a follow-up appointment was scheduled by the treating haematologist. Of all patients, 63.5 % were treated with an intravenous iron preparation during their first examination at the outpatient clinic and a transfusion of erythrocytes was administered during such an examination to 4.3 % of the patients.</p>
            <p>Conclusion: Patients with IDA were often treated at our Haematology Outpatient Clinic in the relevant two-year period. The data indicates a poor recognition rate of this prevalent type of anaemia. IDA is not a blood disorder and the referral of IDA patients to the Haematology Outpatient Clinic is justified in the case of severe microcytic anaemia, when the patient does not respond to the oral or intravenous iron replacement therapy or if a concomitant change in the CBC persists despite the effective treatment with iron preparations.</p>
         </abstract>
      </front-stub>
      <body>
         <sec id="en-s1" sec-type="Introduction">
            <label>1</label>
            <title>Introduction</title>
            <p>Iron-deficiency anemia (IDA) is the only anaemia that affects the wealthy and the poor alike. In the developed world it is more common in women of childbearing age with heavy menstrual bleeding (<xref ref-type="bibr" rid="en-b1">1</xref>). Its prevalence is higher in individuals taking non-steroid antirheumatic drugs and proton pump inhibitors, in the latter most probably because of ulcer disease and decreased gastric juice acidity (<xref ref-type="bibr" rid="en-b2">2</xref>). Inadequate nutrition only rarely causes iron-deficiency anaemia (IDA) in the developed world. However, it may occur in individuals following weird diets (<xref ref-type="bibr" rid="en-b1">1</xref>).The causes of IDA can be most bizarre: e.g. this form of anaemia is encountered in people with Munchausen syndrome (<xref ref-type="bibr" rid="en-b3">3</xref>). In the developing countries, it affects mostly children, adolescents and pregnant women as a result of inadequate nutrition and parasitic infections (<xref ref-type="bibr" rid="en-b1">1</xref>). In men and menopausal women diagnosed with IDA, the first step should be ruling out gastrointestinal cancer (<xref ref-type="bibr" rid="en-b4">4</xref>). Treating IDA patients with iron supplements is only a symptomatic measure. It is of key importance to discover and eliminate the cause of the disease. The paper reviews the results obtained over a two-year period for patients referred to the outpatient clinic of the Department of Haematology with the diagnosis of IDA and patients diagnosed with IDA on the basis of history, clinical and laboratory findings. The paper focuses on the recognition of IDA, identification of its causes, oral and intravenous iron supplementation and management of patients who fail to respond adequately to iron supplementation.</p>
         </sec>
         <sec id="en-s2" sec-type="Material and methods">
            <label>2</label>
            <title>Material and methods</title>
            <p>This retrospective analysis includes the records of 277 patients with the diagnosis of IDA referred to the outpatient clinic of the Department of Haematology between 1 January 2014 and 31 December 2015, including the patients who were diagnosed with IDA on the basis of clinical examination and laboratory tests done in the heamatology clinic. The analysis focused on patient age and gender, referral diagnosis, presence of symptoms and signs of anaemia, haemoglobin levels, erythrocyte levels, mean corpuscular volume (MCV), total iron binding capacity (TIBC), serum ferritin, concomitant blood changes and the presence of menopause in women. In addition, the associated chronic diseases and inflammations that could have led to the onset of anaemia of chronic disease were recorded. The data collected included the patient's comorbidities, inflammatory parameters, urea, uric acid and creatinine levels and liver enzymes. The number of patients scheduled for follow-up examination at the haematology outpatient clinic, the reason for control examination, the treatment modallity prescribed by the patient's GP prior to his/her attendance at the clinic, and the therapy was prescribed on the patient's first visit to the haematology outpatient clinic were also recorded. <table-wrap position="float" id="en-table1" orientation="portrait">
                  <label>Tabela 1:</label>
                  <caption>
                     <p> Classification of anaemias by Hb levels.</p>
                  </caption>
                  <table>
                     <colgroup span="1">
                        <col span="1"/>
                        <col span="1"/>
                     </colgroup>
                     <thead>
                        <tr>
                           <th rowspan="1" colspan="1">Type of anaemia</th>
                           <th align="center" rowspan="1" colspan="1">Hb levels</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td rowspan="1" colspan="1">mild</td>
                           <td rowspan="1" colspan="1">
                              <p>100–120 g/L (women)</p>
                              <p>100–130 g/L (men)</p>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">moderate</td>
                           <td align="right" rowspan="1" colspan="1">70–100 g/L</td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">severe</td>
                           <td align="right" rowspan="1" colspan="1">&lt; 70 g/L</td>
                        </tr>
                     </tbody>
                  </table>
               </table-wrap>
               <xref ref-type="table" rid="en-table1">Table 1</xref> presents the distribution of anaemias by haemoglobin levels. The data were collected using the Hipokrat computer-based information system and statistically evaluated with Microsoft Excel.</p>
            <table-wrap position="anchor" id="en-table2" orientation="portrait">
               <label>Table 2:</label>
               <caption>
                  <p> Mean RBC indices and iron levels</p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th rowspan="1" colspan="1">Laboratory parameters</th>
                        <th rowspan="1" colspan="1">Women</th>
                        <th rowspan="1" colspan="1">Men</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td rowspan="1" colspan="1">Mean Hg levels (g/L)</td>
                        <td rowspan="1" colspan="1">100,5 (σ = ± 20,4)</td>
                        <td rowspan="1" colspan="1">101,5 (σ = ± 23,3)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Mean RBC count (10<sup>12</sup>/L)</td>
                        <td rowspan="1" colspan="1">4,18 (σ = ± 0,62)</td>
                        <td rowspan="1" colspan="1">4,13 (σ = ± 0,95)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Mean serum iron levels (µmol/L)</td>
                        <td align="center" colspan="2" rowspan="1">8,3 (σ = ± 10,9)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Mean ferritin levels (µg/L)</td>
                        <td align="center" colspan="2" rowspan="1">21,6 (σ = ± 70,5)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Mean TIBC (µmol/L)</td>
                        <td align="center" colspan="2" rowspan="1">71,3 (σ = ± 10,6)</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <p>TIBC –total iron binding capacity; ơ- standard deviation (SD)</p>
               </table-wrap-foot>
            </table-wrap>
            <p>The following reference levels were used in the study:</p>
            <list>
               <list-item>
                  <label>•</label>
                  <p>Haemoglobin 120–160 g/L for women and 130–180 g/L for men (<xref ref-type="bibr" rid="en-b5">5</xref>)</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>Haematocrit 0.30–0.47 for women and 0.40–0.54 for men; MCV 82–98 fL; RBC 4,2–5,4 × 10<sup>12</sup>/L for women and 5,4–6,3 × 10<sup>12</sup>/L for men; WBC 3.9–11.1 × 10<sup>9</sup>/L; platelets 157–384 × 10<sup>9</sup>/L (<xref ref-type="bibr" rid="en-b6">6</xref>).</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>Serum iron:10.7–28.6 µmol/L; ferritin 10–120 µg/L for women and 20–300 µg/L for men; TIBC 44.8–80.6 µmol/L; increased CRP &gt; 5 mg/L; creatinine 44–97 µmol/L; elevated AST 3-fold the upper limit (0.52 µkat/L) for women and 3-fold the upper limit (0.58 µkat/L) for men; increased ALT 3-fold the upper limit (0.56 µkat/L) for women and 3-fold the upper limit (0.74 µkat/L) for men (<xref ref-type="bibr" rid="en-b7">7</xref>).</p>
               </list-item>
            </list>
            <p>The study was approved by the Medical Ethics Committee of the Republic of Slovenia on 14 Nov.2017 (no.0120–583/217/5).</p>
         </sec>
         <sec id="en-s3" sec-type="Results">
            <label>3</label>
            <title>Results</title>
            <p>The analysis included data for 277 patients seen for IDA at the outpatient clinic of the Department of Heamatology between 1 January 2014 and 31 December 2015. There were 32 men (11.6 %) and 245 women (88.4 %), of these 172 (62.1 %) were women of reproductive age and 73 ( 26.3 %) were menopausal women. The median age of men was 66.5 years (range 21–87 yrs) and the median age of women 44 years (range 18–94 yrs). <xref ref-type="table" rid="en-table2">Table 2</xref> shows mean RBC parameters. The majority of the referred patients had Hb levels in the range of mild or moderate anaemia. In slightly less than one fifth of the examined patients, Hb levels were within reference range. <xref ref-type="fig" rid="en-fig1">Figure 1</xref> indicates the classification of anaemias by Hb levels.</p>
            <p>Other referral diagnoses included: sweating, monoclonal spike, malaise, monoclonal immunoglobulin of undetermined significance, suspected myelodysplastic syndrome (MDS), suspected thalassemia, pancytopenia, chronic anaemia, macrocytosis, B12 deficiency, peripheral neuropathy, suspected haemolytic anaemia, positive Coombs test, jaundice and others.</p>
            <fig position="anchor" id="en-fig1" orientation="portrait">
               <label>Figure 1:</label>
               <caption>
                  <p> Classification of anaemias by Hb level. N = 277</p>
               </caption>
               <p>
                  <graphic xlink:href="2523-en-web-resources/image/zdravvestn-2523-en-01.png"
                           position="float"
                           orientation="portrait"/>
               </p>
            </fig>
            <p>Twelve patients (4.3 %) were referred to the clinic for an urgent exmination. One of these had mild, seven had moderate and six severe anemia.</p>
            <table-wrap position="anchor" id="en-table3" orientation="portrait">
               <label>Table 3:</label>
               <caption>
                  <p> shows the most common GP referral diagnoses of patients diagnosed with IDA at the heamatology outpatient clinic.</p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th rowspan="1" colspan="1">Referral diagnosis</th>
                        <th align="right" rowspan="1" colspan="1">n = 277 (%)</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td rowspan="1" colspan="1">Iron-deficiency anaemia</td>
                        <td align="right" rowspan="1" colspan="1">108 (39)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Microcytic anaemia</td>
                        <td align="right" rowspan="1" colspan="1">77 (27,8)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Anaemia</td>
                        <td align="right" rowspan="1" colspan="1">30 (10,8)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Leukopenia</td>
                        <td align="right" rowspan="1" colspan="1">5 (1,8)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Thrombocytopenia</td>
                        <td align="right" rowspan="1" colspan="1">5 (1,8)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Iron deficiency</td>
                        <td align="right" rowspan="1" colspan="1">4 (1,4)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Bicytopenia</td>
                        <td align="right" rowspan="1" colspan="1">4 (1,4)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Normocytic anaemia</td>
                        <td align="right" rowspan="1" colspan="1">4 (1,4)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Other diagnoses</td>
                        <td align="right" rowspan="1" colspan="1">40 (14,6)</td>
                     </tr>
                  </tbody>
               </table>
            </table-wrap>
            <p>On physical examination at the haematology outpatient clinic, pallor was the only sign of anaemia reported. It was documented in 145 (52.3 %) patients.</p>
            <p>
               <xref ref-type="table" rid="en-table4">Table 4</xref> shows that anaemia was frequently associated with other CBC changes.</p>
            <p>
               <xref ref-type="table" rid="en-table5">Table 5</xref> indicates that at least one concomitant condition was present in 139 referred patients (50.2 %).</p>
            <table-wrap position="anchor" id="en-table4" orientation="portrait">
               <label>Table 4:</label>
               <caption>
                  <p> Classification of anaemias by concomitant changes in CBC</p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th rowspan="1" colspan="1">Concomitant change in CBC</th>
                        <th align="right" rowspan="1" colspan="1">n = 277 (%)</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td rowspan="1" colspan="1">Leukopenia</td>
                        <td align="right" rowspan="1" colspan="1">21 (7,6)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Leukocytosis</td>
                        <td align="right" rowspan="1" colspan="1">16 (5,8)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Thrombocytopenia</td>
                        <td align="right" rowspan="1" colspan="1">20 (7,2)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Thrombocytosis</td>
                        <td align="right" rowspan="1" colspan="1">46 (16,6)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Pancytopenia</td>
                        <td align="right" rowspan="1" colspan="1">4 (1,4)</td>
                     </tr>
                  </tbody>
               </table>
            </table-wrap>
            <p>Three or more associated diseases were diagnosed in 35 (12.6 %) patients with IDA.</p>
            <table-wrap position="anchor" id="en-table5" orientation="portrait">
               <label>Table 5:</label>
               <caption>
                  <p> Comorbidities in IDA patients</p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th rowspan="1" colspan="1">Concomitant disease/condition</th>
                        <th align="right" rowspan="1" colspan="1">n = 277 (%)</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td rowspan="1" colspan="1">Type 2 diabetes</td>
                        <td align="right" rowspan="1" colspan="1">23 (8,3)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Autoimmune disorder*</td>
                        <td align="right" rowspan="1" colspan="1">23 (8,3)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Hypothyroidism</td>
                        <td align="right" rowspan="1" colspan="1">18 (6,5)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Cancer</td>
                        <td align="right" rowspan="1" colspan="1">8 (2,9)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Heart failure</td>
                        <td align="right" rowspan="1" colspan="1">8 (2,9)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Occult GI bleeding</td>
                        <td align="right" rowspan="1" colspan="1">6 (2,2)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Pregnancy</td>
                        <td align="right" rowspan="1" colspan="1">5 (1,8)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Chronic renal failure</td>
                        <td align="right" rowspan="1" colspan="1">3 (1,1)</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Other</td>
                        <td align="right" rowspan="1" colspan="1">69 (24,9)</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <p>* ulcerative colitis, Chron's disease, rheumatoid arthritis, Hashimoto thyroiditis, coeliac disease, Sjögren syndrome, systemic sclerosis, type1 diabetes.</p>
               </table-wrap-foot>
            </table-wrap>
            <p>In the group of patients with a history of chronic diseases, 54 (19.5 %) patients had increased CRP, five (1.8 %) showed abnormal liver transaminase levels, and one female patient had elevated urea and creatinine levels. ACD associated with IDA was diagnosed in four female patients (1.4 %).</p>
            <p>A total of 173 (62.5 %) patients were scheduled for a follow-up appointment with the haematologist. Of these, 133 (48 %) attended for follow-up examination after iron supplementation.The haematologist ordered additional diagnostic procedures for IDA in 144 (52 %) cases.</p>
            <fig position="anchor" id="en-fig2" orientation="portrait">
               <label>Figure 2:</label>
               <caption>
                  <p> Changes of laboratory patameters on the onset of negative iron balance.</p>
               </caption>
               <p>
                  <graphic xlink:href="2523-en-web-resources/image/zdravvestn-2523-en-02.png"
                           position="float"
                           orientation="portrait"/>
               </p>
               <p>TIBC–total iron binding capacity; RDW–red cell distribution width. Source: Alleyne et al. (<xref ref-type="bibr" rid="en-b8">8</xref>).</p>
            </fig>
            <p>One hundred and sixty-three (58.8 %) patients had been treated for IDA in the past or were taking iron supplements at their first appointment at the clinic. Oral iron supplements were taken by 144 (52 %) patients; 30 (10.8 %) were treated by intravenous iron supplementation and nine (3.2 %) patients by transfusion of red cell concentrate (RCC). For the rest of the patients no data are available. Of all the patients examined, 210 (75.8 %) received treatment or instructions for treatment. Of these 176 (83.9 %) were treated with intravenous iron preparations, and 12 (5.5 %) with transfusion of RCC. Nine (30 %) patients who were given intravenous iron supplement at their first visit to the outpatient clinic received repeat dose of intravenous iron when seen at the haematology outpatient clinic. Fourty-one (28.5 %) patients initially treated with oral iron supplements continued to take iron per os after their follow-up examination. At follow-up examination, nine (2.9 %) patients received a transfusion of RCC.</p>
         </sec>
         <sec id="en-s4" sec-type="Discussion">
            <label>4</label>
            <title>Discussion</title>
            <p>IDA is the most common anaemia and is not regarded as a true blood disorder. The study showed that 277 patients with IDA – i.e.2.7 patients per day – were treated at the Department of Haematology over a 2-year period. There was a predominance of women of reproductive age. The most likely reason for anaemia in this population is menstrual blood loss.</p>
            <p>Absorption of iron is limited to 1 to 2 mg daily and most iron needed for erythropoiesis is provided through metabolic switch of macrophages that phagocytose senescent erythrocytes (<xref ref-type="bibr" rid="en-b1">1</xref>). In clinically significant iron deficiency, depletion of bodyiron stores is reflected in the blood by a decrease in serum ferritin levels (<xref ref-type="bibr" rid="en-b8">8</xref>). Depletion of iron stores leads to disturbances in haemoglobin synthesis and production of hypochromic microcytic erythrocytes in the bone marrow. As indicated by <xref ref-type="fig" rid="en-fig2">Figure 2</xref>, clinically significant forms of iron deficiency develop gradually.</p>
            <fig position="anchor" id="en-fig3" orientation="portrait">
               <label>Figure 3:</label>
               <caption>
                  <p> The proposed diagnostic workup for microcytic anaemia</p>
               </caption>
               <p>
                  <graphic xlink:href="2523-en-web-resources/image/zdravvestn-2523-en-03.png"
                           position="float"
                           orientation="portrait"/>
               </p>
               <p>MCV – mean corpuscular volume, RBC– red blood count, TIBC– total iron binding capacity.</p>
            </fig>
            <p>It is estimated that women of reproductive age lose 1 to 3 mg of iron daily; the intake of iron is often inadequate to maintain iron balance (<xref ref-type="bibr" rid="en-b1">1</xref>). In addition to heavy menstrual bleeding, the most common causes of IDA in the developed world include gastrointestinal bleeding, impaired iron absorption and unusual fad diets (<xref ref-type="bibr" rid="en-b1">1</xref>). In developing countries, IDA most commonly occurs as a result of poor nutrition in people living in poverty.</p>
            <p>In women with menorrhagia disorders of primary haemostasis should be considered (<xref ref-type="bibr" rid="en-b9">9</xref>). Von Willebrand disease affects approx.1 % of the general population and more than 5 % of women with menorrhagia (<xref ref-type="bibr" rid="en-b10">10</xref>). Women with heavy menstrual bleeding have a higher prevalence of abnormal platelet function (<xref ref-type="bibr" rid="en-b9">9</xref>). Further diagnostic testing in pre-menopausal women with IDA is the domain of a GP or a gynaecologist. Even in young women IDA may be brought about by occult gastrointestinal bleeding. Screening for blood in the stool should be done at least six times in a row (<xref ref-type="fig" rid="en-fig3">Figure 3</xref>).</p>
            <p>One-third of the IDA patients seen in the haematology outpatient clinic were older males and menopausal females in whom IDA is very likely due to gastrointestinal diseases (<xref ref-type="bibr" rid="en-b1">1</xref>). Gastrointestinal diagnostic testing in this population is imperative (<xref ref-type="bibr" rid="en-b4">4</xref>). Endoscopic procedures are done to rule out gastrointestinal malignancies, mucosal inflammation, ulcers and angiodysplasia (<xref ref-type="bibr" rid="en-b1">1</xref>). Another cause of IDA may be haemorrhoidal bleeding. After ruling out gastrointestinal haemorrhage, impaired iron absorption that may be due to <italic toggle="yes">Heliobacter pylori</italic> infection, coeliac disease and chronic inflammatory bowel diseases should be considered in all age groups. IDA due to bleeding in the urinary tract is rare. History of unusual dietary patterns and medication should be reviewed in both sexes (<xref ref-type="bibr" rid="en-b11">11</xref>). IDA may occur as a result of the therapy with non-steroid anti-rheumatic drugs, salicylates, warfarin, clopidogrel, heparin, glucocorticoids and proton pump inhibitors (<xref ref-type="bibr" rid="en-b1">1</xref>). Anaemia is a symptom rather than a disease and it is necessary to determine its aetiology.</p>
            <table-wrap position="anchor" id="en-table6" orientation="portrait">
               <label>Table 6:</label>
               <caption>
                  <p> Oral iron preparations for the treatment of IDA</p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th rowspan="1" colspan="1">Brand name</th>
                        <th rowspan="1" colspan="1">Substance</th>
                        <th rowspan="1" colspan="1">Packaging</th>
                        <th rowspan="1" colspan="1">Dosage*</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td rowspan="1" colspan="1">Ferrum Lek®</td>
                        <td rowspan="1" colspan="1">trivalent iron oxide</td>
                        <td rowspan="1" colspan="1">
                           <p>30 × 100 mg</p>
                           <p>chewable tablets</p>
                           <p>100 ml of syrup</p>
                           <p>50 mg/5 ml</p>
                        </td>
                        <td rowspan="1" colspan="1">
                           <p>1–3 tbs/day</p>
                           <p>10–30 ml/day</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">
                           <p>Eisensulfat</p>
                           <p>Lomapharm®</p>
                        </td>
                        <td rowspan="1" colspan="1">two-valent ferrous sulphate</td>
                        <td rowspan="1" colspan="1">
                           <p>20 x, 50x, 100x</p>
                           <p>100 mg tablets</p>
                        </td>
                        <td rowspan="1" colspan="1">1 tb/12 hours</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Legofer®</td>
                        <td rowspan="1" colspan="1">trivalent iron proteinsukcinalat</td>
                        <td rowspan="1" colspan="1">
                           <p>150 ml of syrup</p>
                           <p>40 mg/15 ml</p>
                        </td>
                        <td rowspan="1" colspan="1">7.5–15 ml/12 hours</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Tardyfer®</td>
                        <td rowspan="1" colspan="1">two-valent iron sulphate</td>
                        <td rowspan="1" colspan="1">30 × 80 mg tablets</td>
                        <td rowspan="1" colspan="1">1–2 tbs/day</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <p>* dosage for adults with overt iron deficiency</p>
               </table-wrap-foot>
            </table-wrap>
            <p>As indicated by <xref ref-type="table" rid="en-table3">Table 3</xref> mean Hb levels in the men and women studied bordered between mild and moderate anaemia. Mean serum iron concentration was expectedly decreased, mean serum ferritin was at the lower border of normal and mean TIBC was within the range of reference levels. Interestingly, nearly one-fifth of the patients had normal Hb levels at their first appointment at the haematology outpatient clinic, which may be explained by the fact that the triage haematologist gives treatment instructions based on the enclosed laboratory results to the patient's GP prior to his/her examination at the clinic.</p>
            <p>A surprisingly large proportion of patients in the study were referred as urgent cases. In half of them, Hb levels were within the range of moderate anaemia and in one female patient they were even suggestive of mild anaemia.</p>
            <p>
               <xref ref-type="table" rid="en-table4">Table 4</xref> shows that a little less than half of the patients were referred to the haematology outpatient clinic with the diagnosis of IDA. In only one-tenth Hb levels were within the range of severe anaemia. Indications for referral of IDA patients to the haematologist included: severe macrocytic anaemia (Hb &lt; 70 g/L), unclear differentiation of IDA from ACD and other abnormalities in CBC that persist despite iron supplementation and increase in the Hb levels.</p>
            <table-wrap position="anchor" id="en-table7" orientation="portrait">
               <label>Table 7:</label>
               <caption>
                  <p> Intravenous iron preparations for the treatment of IDA</p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th rowspan="1" colspan="1">Brand name</th>
                        <th rowspan="1" colspan="1">Substance and carrier</th>
                        <th rowspan="1" colspan="1">Packaging</th>
                        <th rowspan="1" colspan="1">Dosage*</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td rowspan="1" colspan="1">Ferrologic®</td>
                        <td rowspan="1" colspan="1">trivalent iron oxide (saccharated)</td>
                        <td rowspan="1" colspan="1">
                           <p>20 mg/ml</p>
                           <p>5-ml ampoules</p>
                        </td>
                        <td rowspan="1" colspan="1">100–200 mg/day to 3 times a week, or max.500 mg once a week</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Iroprem®</td>
                        <td rowspan="1" colspan="1">trivalent iron carboxymaltose</td>
                        <td rowspan="1" colspan="1">
                           <p>50 mg/ml</p>
                           <p>10-ml vials</p>
                           <p>2-ml vials</p>
                        </td>
                        <td rowspan="1" colspan="1">
                           <p>max.1000 mg/day</p>
                           <p>once a week</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Venofer®</td>
                        <td rowspan="1" colspan="1">Trivalent iron oxide (saccharated)</td>
                        <td rowspan="1" colspan="1">
                           <p>20 mg/ml</p>
                           <p>5-ml ampoules</p>
                        </td>
                        <td rowspan="1" colspan="1">
                           <p>100–200 mg/day to</p>
                           <p>3 times a week or max.500 mg once a week</p>
                        </td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <p>*total cummulative dose of IV iron is calculated as follows:</p>
                  <p>Ferrologic® and Venofer®</p>
                  <p>Total amount of iron to be administered (mg) = body mass (kg) x (target Hg concentration – actual Hb concentration (g/l) × 0.24* + amount of iron needed to fill up body iron stores (500 mg)</p>
                  <p>Iroprem®</p>
                  <p>Patients with BMI 35 kg to &lt; 70 kg; Hb &lt; 10 g/dl: 1,500 mg, Hb ≥ 10 g/dl: 1,000 mg</p>
                  <p>Patients with BMI ≥ 70 kg; Hb &lt; 10 g/dl: 2,000 mg, Hb ≥ 10 g/dl: 1,500 mg.</p>
               </table-wrap-foot>
            </table-wrap>
            <p>IDA remains a condition with low recognition rate. As many as one-third of patients were referred to the clinic with the diagnosis of microcytic anaemia, which is surprising considering the fact that IDA is known to be by far the most common cause of microcytic anaemia. In addition to low Hb levels and the associated microcytosis, the evidence of reduced body's iron stores (decreased serum iron and decreased serum ferritin levels) is necessary to confirm the diagnosis of IDA (<xref ref-type="bibr" rid="en-b1">1</xref>,<xref ref-type="bibr" rid="en-b11">11</xref>). MCV is considered a nonspecific index as the presence of normocytic anaemia does not exclude iron deficiency (<xref ref-type="bibr" rid="en-b12">12</xref>). A combination of IDA and vitamin B12 or folate deficiency should also be considered. In addition to IDA, the differential diagnosis of microcytic anaemia should include ACD and thalassemia minor (<xref ref-type="bibr" rid="en-b11">11</xref>).</p>
            <p>ACD is a form of anaemia seen in chronic diseases, chronic infection, chronic inflammation and malignancy (<xref ref-type="bibr" rid="en-b11">11</xref>). It is characterised by elevated levels of the hormone hepcidin, which inhibits intestinal iron absorption and release of iron from body iron stores. Laboratory findings therefore include low serum iron, elevated serum ferritin and, frequently, decreased TIBC concentration. Serum ferritin is not a relevant parameter in the assessment of body iron stores in ACD (<xref ref-type="bibr" rid="en-b13">13</xref>).</p>
            <p>Beta thalassemia minor is the most common haemoglobinopathy in Slovenia (<xref ref-type="bibr" rid="en-b14">14</xref>). It affects mostly individuals with Mediterranean and Balkan ancestors. In the future its prevalence is likely to increase with international migration flows. Patients with beta thalassemia minor, as a rule, experience no clinical symptoms. They have mild anaemia (Hb levels of around 100 g/L) pronounced microcytosis (MCV of 60–70 fl) and normal RBC count (<xref ref-type="bibr" rid="en-b15">15</xref>). Typically, there is a disproportion between Hb levels and pronounced microcytosis. Examination of the peripheral blood smear reveals target erythrocytes and basophilic punctation of erythrocytes, with prevailing dacriocytes and ovalocytes (<xref ref-type="bibr" rid="en-b16">16</xref>). In patients with suspected thalassemia minor, haemoglobin electrophoresis is used instead of unpleasant endoscopic examinations to confirm abnormal findings.</p>
            <p>Once the diagnosis of microcytic anaemia is made, the patient's body iron status, i.e serum iron, serum ferritin and TIBC levels, should be determined (<xref ref-type="bibr" rid="en-b11">11</xref>). Patients with IDA have low serum iron and serum ferritin and high TIBC concentrations. Reduced ferritin is the most reliable parameter used to confirm IDA (<xref ref-type="bibr" rid="en-b17">17</xref>). Normal ferritin levels in the serum with concurrent low serum iron levels do not rule out IDA, as IDA may be associated with ACD (<xref ref-type="bibr" rid="en-b11">11</xref>,<xref ref-type="bibr" rid="en-b13">13</xref>).</p>
            <p>Iron homeostasis is a process regulated mainly by hepcidin, a hormone present in the liver (<xref ref-type="bibr" rid="en-b11">11</xref>). Elevated plasma levels of iron induce secretion of hepcidin from the liver. By binding to the transmembrane iron transporter ferroportin it causes its degradation and thereby inhibits iron release from the duodenum and delivery from the reticuloendothelial system in the blood. Chronic inflammations and infections enhance hepcidin secretion from the liver and reduce the levels of serum iron, which is stored in adequate amounts in the body. The condition is known as functional iron deficiency. It is differentiated from manifested iron deficiency by high levels of storage iron, confirmed by high serum ferritin concentration.</p>
            <p>As concluded by clinical studies, patients with chronic diseases have iron deficiency when their ferritin levels drop below 100 µg/L (<xref ref-type="bibr" rid="en-b18">18</xref>). There is, however, some discrepancy between the authors. According to some investigators (<xref ref-type="bibr" rid="en-b2">2</xref>,<xref ref-type="bibr" rid="en-b19">19</xref>) ferritin concentration associated with iron deficiency is 200 µg/L. Final recommendations are still awaited. In Slovenia, patients with ACD are treated with iron supplements when their ferritin levels drop below 100 µg/L. These patients do not respond to oral iron replacement, therefore invariably intravenous therapy is used (<xref ref-type="bibr" rid="en-b19">19</xref>,<xref ref-type="bibr" rid="en-b20">20</xref>).</p>
            <p>One-third of the patients studied presented with concomitant chronic diseases. The laboratory parameters that help us determine the combined aetiology of microcytic anaemia include: transferrin saturation, soluble transferrin receptor levels, reticulocyte haemoglobin content and hepcidin levels (<xref ref-type="bibr" rid="en-b19">19</xref>). It is possible to measure those parameters in the laboratory of the Department of Haematology but are not routinely done.</p>
            <p>Low serum iron levels indicate iron deficiency. Serum iron, however, is not a reliable index of body iron stores because of the role played by the individual's diet. After patient with IDA ingest food high in iron, serum iron can rise. Misled by these results, the physician may assume that the patient's iron stores are adequate, yet in the absence of ACD, low ferritin concentration are the key index of the body's stores of iron. Because of fluctuations caused by diurnal variation, serum iron levels are the highest in the morning and at noon, and decrease gradually in the afternoon (<xref ref-type="bibr" rid="en-b21">21</xref>). Iron is an ideal food source for microorganisms, therefore individuals with high levels of serum iron are prone to infections and septic conditions (<xref ref-type="bibr" rid="en-b35">35</xref>,<xref ref-type="bibr" rid="en-b36">36</xref>).</p>
            <p>Patients who present to the haematology outpatient clinic often provide results of blood tests and serum iron determination without data of serum ferirtin concentration. This information is of key importance in the management of patients with IDA and should therefore always be included in the patient's referral medical documentation.</p>
            <p>Clinical presentation of anaemia is well known, but it is of primary importance to obtain information on the speed of onset of the disease. Patients with chronic anaemia, even those with severe microcytic anaemia, are often free of symptoms. The authors have experience in treating Jehowah's Witnesses who attended for follow-up examinations until their Hb levels were less than 40 g/L. Pallor was documented in only half of the study patients seen in the haematology clinic. It is a matter of the haematologist's subjective judgement. This sign is only rarely mentioned in the patient's record. Haematologists, faced with overcrowded waiting rooms, work fast and may therefore be inaccurate. Iron replacement therapy is instituted also in patients who complain of severe fatigue, exertional dyspnea and palpitations.</p>
            <p>
               <xref ref-type="table" rid="en-table4">Table 4</xref> shows that many study patients with anaemia had concomitant CBC abnormalities. IDA is often accompanied with changes of CBC (<xref ref-type="bibr" rid="en-b22">22</xref>), the most common being reactive thrombocytosis. It was present in one-sixth of the study patients. The exact causative mechanism of reactive thrombocytosis in patients with IDA is unknown (<xref ref-type="bibr" rid="en-b23">23</xref>). Some studies explain it as a synergistic effect of erythropoeitin on platelet formation (<xref ref-type="bibr" rid="en-b24">24</xref>). It makes sense that patients presenting with anaemia and thrombocytosis have a peripheral smear test to rule out the presence of IDA. According to the literature data reactive leukopenia is encountered in 2–17 % of IDA patients (<xref ref-type="bibr" rid="en-b25">25</xref>,<xref ref-type="bibr" rid="en-b26">26</xref>). It tends to be mild with iron levels of 3.0 × 10<sup>9</sup>/L or higher (<xref ref-type="bibr" rid="en-b22">22</xref>). In this review, leukopenia was recorded in 7 % of cases. A similar proportion of patients had thrombocytopenia, which, according to the literature, is less frequently associated with IDA (<xref ref-type="bibr" rid="en-b27">27</xref>,<xref ref-type="bibr" rid="en-b28">28</xref>). In patients with a combination of anaemia and thrombocytopenia it is necessary to consider thrombotic microangiopathy or any of its forms, such as thrombotic thrombocytopenic purpura and haemolytic uremic syndrome, chracterised by typical clinical manifestations and abnormal laboratory findings. A few cases of pancytopenia have been documented, yet the disorder rarely occurs in patients with IDA (<xref ref-type="bibr" rid="en-b29">29</xref>). Low counts of all blood cells are more often found in megaloblastic anaemia (<xref ref-type="bibr" rid="en-b30">30</xref>). Iron supplementation usually makes all the aforementioned changes in CBC disappear. If IDA goes away but other abnormal CBC findings persist, the patient needs further haematologic evaluation to exclude possible concomitant blood disorders (<xref ref-type="bibr" rid="en-b22">22</xref>).</p>
            <p>A surprisingly large number of patients were invited to attend for a follow-up examination, in our opinion, the majority of them for no clear reason. Following a patient with IDA is the domain of the patient's GP.</p>
            <p>Prior to their visit to the haematology outpatient clinic more than half of the patients were taking iron supplements. IDA is invariably treated with iron replacement. Oral iron is the first-choice treatment for haemodynamically stable IDA patients (<xref ref-type="bibr" rid="en-b1">1</xref>). The recommended dosage for adult patients is 200 mg divided into morning and evening doses. The duration of iron replacement therapy is three months. Haemoglobin levels are expected to increase by 20 g/L over three weeks ( 1 g/L daily) (<xref ref-type="bibr" rid="en-b20">20</xref>,<xref ref-type="bibr" rid="en-b31">31</xref>). In order to fill up iron stores, treatment with iron supplements at a dose of 100 mg daily is continued for further three to six months (<xref ref-type="bibr" rid="en-b32">32</xref>).</p>
            <p>For better iron absorption iron supplements should be taken on an empty stomach or at least two hours after meals, together with vitamin C (<xref ref-type="bibr" rid="en-b1">1</xref>). Some authors recommend taking iron supplements with a meat-based meal (<xref ref-type="bibr" rid="en-b11">11</xref>). Iron absorption is impaired by a simultaneous ingestion of calcium (milk and dairy products), tannin (black tea, some herbal teas, red wine), phytates (cereals, grains) and caffeine (<xref ref-type="bibr" rid="en-b33">33</xref>).</p>
            <p>Gastrointestinal problems that may be caused by iron supplements are the most common reason for unsuccessful therapy (<xref ref-type="bibr" rid="en-b11">11</xref>). Taking iron on a regular basis is more important for the effective therapy than the choice between two- and three-valent iron supplements (<xref ref-type="bibr" rid="en-b1">1</xref>). Some manufacturers recommend slow-release formulations, yet from these preparations iron is released in the digestive tract distal to the duodenum where no absorption takes place (<xref ref-type="bibr" rid="en-b1">1</xref>). The principal site for iron absorption if the upper gastrointestinal tract, i.e. in the upper half of the duodenum. Side-effects of therapy are therefore more pronounced. Iron supplements cause black stools, yet faecal occult blood tests are negative (<xref ref-type="bibr" rid="en-b1">1</xref>).</p>
            <p>The newer understanding of the role of hepcidin has led to changes in the treatment with oral supplements. Recent studies showed that a single daily dose of iron increases hepcidin levels in blood and decreases absorption of iron from subsequent doses. The effect of hepcidin may be apparent for up to 48 hours (<xref ref-type="bibr" rid="en-b37">37</xref>). The present recommended dosing scheme will probably be a single daily dose of iron supplement taken on alternate days (<xref ref-type="bibr" rid="en-b38">38</xref>). Further clinical research are needed in this field. Currently, standard dosing of oral iron is recommended as described in this paper.</p>
            <p>If a 4- to 6-week treatment with elemental iron of 100 mg daily fails to increase haemoglobin levels by 10 g/L, the diagnosis of refractory IDA is made (<xref ref-type="bibr" rid="en-b20">20</xref>). Common causes of refractory IDA include: coeliac disease, autoimmune atrophic gastritis, gastritis caused by <italic toggle="yes">H.pylori</italic> infection and iron refractory iron deficiency anaemia (IRIDA), a hereditary form of IDA (<xref ref-type="bibr" rid="en-b20">20</xref>). IDA is the most common extraintestinal manifestation of coeliac disease. It occurs as a result of a combination of impaired iron absorption and occult bleedings (<xref ref-type="bibr" rid="en-b20">20</xref>). Gastric hypoacidity in autoimmune atrophic gastritis impairs oral iron solubility (<xref ref-type="bibr" rid="en-b20">20</xref>). Clinical studies have confirmed the connection between refractory IDA and gastritis caused by <italic toggle="yes">H.pylori</italic> infection. A clear mechanism behind the effect of this microorganism on iron uptake, occult bleedings and gastric juice alkalisation is yet unknown (<xref ref-type="bibr" rid="en-b20">20</xref>). Eradication of <italic toggle="yes">H.pylori</italic> infection and simultaneous iron replacement therapy have proved effective in treating IDA in most cases (<xref ref-type="bibr" rid="en-b34">34</xref>). IRIDA is a rare hereditary condition caused by mutations in TMPRSS6 gene which encodes matriptase 2 enzyme (<xref ref-type="bibr" rid="en-b1">1</xref>), affecting the regulation of hepcidin secretion. This disease is characterised by very high hepcidin levels that impair absorption of iron from the digestive tract. Iron status in hypochromic microcytic anaemia in similar to that in ACD: serum iron levels are very low, while serum ferritin is normal or even elevated. Absence of inflammatory signs differentiates it from ACD. It affects more commonly children and young adults.</p>
            <p>Indications for intravenous iron therapy include: intolerance of iron preparations, refractory anaemia associated with iron deficiency, refusal of transfusion based on religious reasons (Jehovah's Witnesses), filling up of iron stores before treatment with erythropoieitin (<xref ref-type="bibr" rid="en-b1">1</xref>). Intravenous iron therapy causes a fast increase in iron serum haemoglobin and is therefore used in IDA patients scheduled for surgery, as well as in women in the second and third month of pregnancy with severe anaemia, and in patients with blood coagulation disorders bleeding from the gastrointestinal tract. Fear of allergic reactions to intravenous iron administration comes from the past when dextran-containing iron preparations were used for intravenous iron replacement (<xref ref-type="bibr" rid="en-b39">39</xref>). Dextran was most often responsible for adverse reactions in these patients. Iron supplements used today contain no dextran and allergic reactions are very rare. Giving the patient intravenous iron supplements in the health care centre is an entirely safe procedure, therefore referral to the haematologist is not justified (<xref ref-type="bibr" rid="en-b40">40</xref>). Costs of treatment are covered under the national health insurance scheme. Intravenous iron replacement in the first trimester of pregnancy is avoided because of a lack of safety studies (<xref ref-type="bibr" rid="en-b40">40</xref>).</p>
            <p>Transfusion of red cell concentrates (RCC) in IDA is symtpomatic and should be reserved for patients with severe clinical problems (<xref ref-type="bibr" rid="en-b1">1</xref>). RCC transfusion is beneficial for healthy individuals with haemoglobin concentrations below 60 g/L. Anaemia is not well tolerated by patients with heart disease; cardiac patients with haemoglobin concentration of less than 100 g/L had higher mortality rates (<xref ref-type="bibr" rid="en-b41">41</xref>). RCC transfusion is usually given after acute bleeding regardless of the site of bleeding. Also, it is administered to patients with major chronic haemorrhage in whom haematopoesis cannot compensate for blood loss, i.e. patients with hereditary haemorrhagic telangiectasia (<xref ref-type="bibr" rid="en-b1">1</xref>). RCC transfusion is indicated in patients with heart failure and chronic renal or liver diseases, and in patients with other chronic conditions who have a higher threshold for transfusion, dependent on symptoms and signs of anaemia. RCC transfusion always worsens the course and outcome of treatment of primary disease.</p>
            <p>In patients receiving RCC transfusion, iron supplementation should be instituted, as a rule, via the intravenous route (<xref ref-type="bibr" rid="en-b42">42</xref>). Erythropoietin has no place in the treatment of IDA.</p>
            <p>Iron supplements used in IDA patients in Slovenia (<xref ref-type="bibr" rid="en-b43">43</xref>):</p>
            <list>
               <list-item>
                  <label>•</label>
                  <p>Oral iron supplements are listed in <xref ref-type="table" rid="en-table6">Table 6</xref>.</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>Intravenous iron preparations are listed in <xref ref-type="table" rid="en-table7">Table 7</xref>
                  </p>
               </list-item>
            </list>
         </sec>
         <sec id="en-s5" sec-type="Conclusion">
            <label>5</label>
            <title>Conclusion</title>
            <p>IDA is a common reason for referring patients to the haematology outpatient clinic. The results of this study show that most of the patients seen in the clinic were women of childbearing age. The majority of patients with IDA received intravenous iron replacement. The results indicate that microcytic anaemia is a condition with low recognition rate. Referral to the haematology outpatient clinic is justified if the patient has severe symptomatic microcytic anaemia (Hb &lt; 70 g/L) or if concomitant changes in the CBC persist despite iron supplementation and with increase in Hb levels.</p>
         </sec>
      </body>
      <back>
         <ref-list>
            <ref id="en-b1">
               <label>1. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Camaschella</surname>
                        <given-names>C</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Iron-deficiency anemia</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2015</year>
                    <month>May</month>;
                    <volume>372</volume>(
                    <issue>19</issue>):
                    <fpage>1832</fpage>–
                    <lpage>43</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMra1401038</pub-id>
                    <pub-id pub-id-type="pmid">25946282</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b2">
               <label>2. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Short</surname>
                        <given-names>MW</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Domagalski</surname>
                        <given-names>JE</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Iron deficiency anemia: evaluation and management</article-title>. 
                    <source>Am Fam Physician</source>. 
                    <year>2013</year>
                    <month>Jan</month>;
                    <volume>87</volume>(
                    <issue>2</issue>):
                    <fpage>98</fpage>–
                    <lpage>104</lpage>.
                    <pub-id pub-id-type="pmid">23317073</pub-id>
                    <issn>1532-0650</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b3">
               <label>3. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Nishimura</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Matsuzaki</surname>
                        <given-names>H</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Fujimoto</surname>
                        <given-names>K</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kawakita</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Takatsuki</surname>
                        <given-names>K</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Münchhausen syndrome with severe iron deficiency anemia</article-title>. 
                    <source>Rinsho Ketsueki</source>. 
                    <year>1992</year>
                    <month>Apr</month>;
                    <volume>33</volume>(
                    <issue>4</issue>):
                    <fpage>478</fpage>–
                    <lpage>82</lpage>.
                    <pub-id pub-id-type="pmid">1602612</pub-id>
                    <issn>0485-1439</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b4">
               <label>4. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Khadem</surname>
                        <given-names>G</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Scott</surname>
                        <given-names>IA</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Klein</surname>
                        <given-names>K</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Evaluation of iron deficiency anaemia in tertiary hospital settings: room for improvement?</article-title>
                    <source>Intern Med J</source>. 
                    <year>2012</year>
                    <month>Jun</month>;
                    <volume>42</volume>(
                    <issue>6</issue>):
                    <fpage>658</fpage>–
                    <lpage>64</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1445-5994.2012.02724.x</pub-id>
                    <pub-id pub-id-type="pmid">22288902</pub-id>
                    <issn>1444-0903</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b5">
               <label>5. </label>
               <mixed-citation publication-type="webpage">
                    <person-group person-group-type="author">
                        <collab>World Health Organ</collab>
                    </person-group>. 
                    <source>Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity</source>.
                    <publisher-loc>Geneva</publisher-loc>:
                    <publisher-name>WHO</publisher-name>;
                    <year>2011</year>. 
                    [<date-in-citation content-type="access-date" iso-8601-date="2017-01-10">cited 2017 Jan 10</date-in-citation>]. 
                    <comment>Available from:<uri>http://www.who.int/vmnis/indicators/haemoglobin.pdf</uri>
                  </comment>.
                </mixed-citation>
            </ref>
            <ref id="en-b6">
               <label>6. </label>
               <mixed-citation publication-type="webpage">
                    <person-group>
                     <name name-style="western">
                        <surname/>
                     </name>
                  </person-group>.
                    <source>Laboratorijski vodnik UKC Ljubljana, INTKOHem- Interna klinika - KO za hematologijo-Specializirani hematološki laboratorij</source>. 
                    [<date-in-citation content-type="access-date" iso-8601-date="2017-01-10">cited 2017 Jan 10</date-in-citation>]. 
                    <comment>Available from:<uri>http://lab.biarti.si/</uri>
                  </comment>.
                </mixed-citation>
            </ref>
            <ref id="en-b7">
               <label>7. </label>
               <mixed-citation publication-type="webpage">
                  <person-group>
                     <name name-style="western">
                        <surname/>
                     </name>
                  </person-group>.
                <source>Laboratorijski vodnik UKC Ljubljana, KIKKB Klinični inštitut za klinično kemijo in biokemijo</source>. 
                [<date-in-citation content-type="access-date" iso-8601-date="2017-01-10">cited 2017 Jan 10</date-in-citation>].
                </mixed-citation>
            </ref>
            <ref id="en-b8">
               <label>8. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Alleyne</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Horne</surname>
                        <given-names>MK</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Miller</surname>
                        <given-names>JL</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Individualized treatment for iron-deficiency anemia in adults</article-title>. 
                    <source>Am J Med</source>. 
                    <year>2008</year>
                    <month>Nov</month>;
                    <volume>121</volume>(
                    <issue>11</issue>):
                    <fpage>943</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.amjmed.2008.07.012</pub-id>
                    <pub-id pub-id-type="pmid">18954837</pub-id>
                    <issn>0002-9343</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b9">
               <label>9. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Mills</surname>
                        <given-names>HL</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Abdel-Baki</surname>
                        <given-names>MS</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Teruya</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Dietrich</surname>
                        <given-names>JE</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Shah</surname>
                        <given-names>MD</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Mahoney</surname>
                        <given-names>D</given-names>
                        <suffix>Jr</suffix>
                     </name>
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Platelet function defects in adolescents with heavy menstrual bleeding</article-title>. 
                    <source>Haemophilia</source>. 
                    <year>2014</year>
                    <month>Mar</month>;
                    <volume>20</volume>(
                    <issue>2</issue>):
                    <fpage>249</fpage>–
                    <lpage>54</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/hae.12293</pub-id>
                    <pub-id pub-id-type="pmid">24251971</pub-id>
                    <issn>1351-8216</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b10">
               <label>10. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Dilley</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Drews</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Miller</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Lally</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Austin</surname>
                        <given-names>H</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Ramaswamy</surname>
                        <given-names>D</given-names>
                     </name>
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia</article-title>. 
                    <source>Obstet Gynecol</source>. 
                    <year>2001</year>
                    <month>Apr</month>;
                    <volume>97</volume>(
                    <issue>4</issue>):
                    <fpage>630</fpage>–
                    <lpage>6</lpage>.
                    <pub-id pub-id-type="pmid">11275041</pub-id>
                    <issn>0029-7844</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b11">
               <label>11. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>DeLoughery</surname>
                        <given-names>TG</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Microcytic anemia</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2014</year>
                    <month>Oct</month>;
                    <volume>371</volume>(
                    <issue>14</issue>):
                    <fpage>1324</fpage>–
                    <lpage>31</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMra1215361</pub-id>
                    <pub-id pub-id-type="pmid">25271605</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b12">
               <label>12. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Johnson-Wimbley</surname>
                        <given-names>TD</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Graham</surname>
                        <given-names>DY</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Diagnosis and management of iron deficiency anemia in the 21st century</article-title>. 
                    <source>Therap Adv Gastroenterol</source>. 
                    <year>2011</year>
                    <month>May</month>;
                    <volume>4</volume>(
                    <issue>3</issue>):
                    <fpage>177</fpage>–
                    <lpage>84</lpage>. 
                    <pub-id pub-id-type="doi">10.1177/1756283X11398736</pub-id>
                    <pub-id pub-id-type="pmid">21694802</pub-id>
                    <issn>1756-283X</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b13">
               <label>13. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Bermejo</surname>
                        <given-names>F</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>García-López</surname>
                        <given-names>S</given-names>
                     </name>
                    </person-group>. 
                    <article-title>A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases</article-title>. 
                    <source>World J Gastroenterol</source>. 
                    <year>2009</year>
                    <month>Oct</month>;
                    <volume>15</volume>(
                    <issue>37</issue>):
                    <fpage>4638</fpage>–
                    <lpage>43</lpage>. 
                    <pub-id pub-id-type="doi">10.3748/wjg.15.4638</pub-id>
                    <pub-id pub-id-type="pmid">19787826</pub-id>
                    <issn>1007-9327</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b14">
               <label>14. </label>
               <mixed-citation publication-type="webpage">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Todorova</surname>
                        <given-names>B</given-names>
                     </name>
                    </person-group>. 
                    <source>Talasemije v Sloveniji</source>.
                    <year>2014</year>. 
                    [<date-in-citation content-type="access-date" iso-8601-date="2017-01-10">cited 2017 Jan 10</date-in-citation>]. 
                    <comment>Available from:<uri>http://www.hematologija.org/admin/files/news/pics/file/Todorova%20B%20p2014.pdf</uri>
                  </comment>.
                </mixed-citation>
            </ref>
            <ref id="en-b15">
               <label>15. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Nuchprayoon</surname>
                        <given-names>I</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Sukthawee</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Nuchprayoon</surname>
                        <given-names>T</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Red cell indices and therapeutic trial of iron in diagnostic work-up for anemic Thai females</article-title>. 
                    <source>J Med Assoc Thai</source>. 
                    <year>2003</year>
                    <month>Jun</month>;
                    <volume>86</volume>
                    <supplement>Suppl 2</supplement>:
                    <fpage>S160</fpage>–
                    <lpage>9</lpage>.
                    <pub-id pub-id-type="pmid">12929984</pub-id>
                    <issn>0125-2208</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b16">
               <label>16. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Körber</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Wölfler</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Neubauer</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Robier</surname>
                        <given-names>C</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Short Communication Red blood cell morphology in patients with β-thalassemia minor</article-title>. 
                    <source>J Lab Med</source>.
                    <year>2016</year>;
                    <volume>41</volume>(
                    <issue>1</issue>):
                    <fpage>49</fpage>–
                    <lpage>52</lpage>.
                    <pub-id pub-id-type="doi">10.1515/labmed-2016-0052</pub-id>
                    <issn>2567-9430 </issn>  
                </mixed-citation>
            </ref>
            <ref id="en-b17">
               <label>17. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Ganz</surname>
                        <given-names>T</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Hepcidin and iron regulation, 10 years later</article-title>. 
                    <source>Blood</source>. 
                    <year>2011</year>
                    <month>Apr</month>;
                    <volume>117</volume>(
                    <issue>17</issue>):
                    <fpage>4425</fpage>–
                    <lpage>33</lpage>. 
                    <pub-id pub-id-type="doi">10.1182/blood-2011-01-258467</pub-id>
                    <pub-id pub-id-type="pmid">21346250</pub-id>
                    <issn>0006-4971</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b18">
               <label>18. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Locatelli</surname>
                        <given-names>F</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Aljama</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bárány</surname>
                        <given-names>P</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Canaud</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Carrera</surname>
                        <given-names>F</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Eckardt</surname>
                        <given-names>KU</given-names>
                     </name>
                        <etal>et al</etal>; 
                        <collab>European Best Practice Guidelines Working Group</collab>
                    </person-group>. 
                    <article-title>Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure</article-title>. 
                    <source>Nephrol Dial Transplant</source>. 
                    <year>2004</year>
                    <month>May</month>;
                    <volume>19</volume>
                    <supplement>Suppl 2</supplement>:
                    <fpage>ii1</fpage>–
                    <lpage>47</lpage>.
                    <pub-id pub-id-type="pmid">15206425</pub-id>
                    <issn>0931-0509</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b19">
               <label>19. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Thomas</surname>
                        <given-names>DW</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Hinchliffe</surname>
                        <given-names>RF</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Briggs</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Macdougall</surname>
                        <given-names>IC</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Littlewood</surname>
                        <given-names>T</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Cavill</surname>
                        <given-names>I</given-names>
                     </name>; 
                        <collab>British Committee for Standards in Haematology</collab>
                    </person-group>. 
                    <article-title>Guideline for the laboratory diagnosis of functional iron deficiency</article-title>. 
                    <source>Br J Haematol</source>. 
                    <year>2013</year>
                    <month>Jun</month>;
                    <volume>161</volume>(
                    <issue>5</issue>):
                    <fpage>639</fpage>–
                    <lpage>48</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/bjh.12311</pub-id>
                    <pub-id pub-id-type="pmid">23573815</pub-id>
                    <issn>0007-1048</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b20">
               <label>20. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Hershko</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Camaschella</surname>
                        <given-names>C</given-names>
                     </name>
                    </person-group>. 
                    <article-title>How I treat unexplained refractory iron deficiency anemia</article-title>. 
                    <source>Blood</source>. 
                    <year>2014</year>
                    <month>Jan</month>;
                    <volume>123</volume>(
                    <issue>3</issue>):
                    <fpage>326</fpage>–
                    <lpage>33</lpage>. 
                    <pub-id pub-id-type="doi">10.1182/blood-2013-10-512624</pub-id>
                    <pub-id pub-id-type="pmid">24215034</pub-id>
                    <issn>0006-4971</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b21">
               <label>21. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Sinniah</surname>
                        <given-names>R</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Doggart</surname>
                        <given-names>JR</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Neill</surname>
                        <given-names>DW</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Diurnal variations of the serum iron in normal subjects and in patients with haemochromatosis</article-title>. 
                    <source>Br J Haematol</source>. 
                    <year>1969</year>
                    <month>Oct</month>;
                    <volume>17</volume>(
                    <issue>4</issue>):
                    <fpage>351</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1365-2141.1969.tb01381.x</pub-id>
                    <pub-id pub-id-type="pmid">5346408</pub-id>
                    <issn>0007-1048</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b22">
               <label>22. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Skopec</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Zver</surname>
                        <given-names>S</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Reaktivne spremembe krvne slike in osnove zdravljenja anemije zaradi pomanjkanja železa</article-title>. 
                    <source>Zdrav Vestn</source>. 
                    <year>2008</year>;
                    <volume>77</volume>(
                    <issue>1</issue>):
                    <fpage>161</fpage>–
                    <lpage>5</lpage>.
                    <issn>0350-0063</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b23">
               <label>23. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Akan</surname>
                        <given-names>H</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Güven</surname>
                        <given-names>N</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Aydogdu</surname>
                        <given-names>I</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Arat</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Beksaç</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Dalva</surname>
                        <given-names>K</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Thrombopoietic cytokines in patients with iron deficiency anemia with or without thrombocytosis</article-title>. 
                    <source>Acta Haematol</source>. 
                    <year>2000</year>;
                    <volume>103</volume>(
                    <issue>3</issue>):
                    <fpage>152</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.1159/000041038</pub-id>
                    <pub-id pub-id-type="pmid">10940653</pub-id>
                    <issn>0001-5792</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b24">
               <label>24. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Bleeker</surname>
                        <given-names>JS</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Hogan</surname>
                        <given-names>WJ</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies</article-title>. 
                    <source>Thrombosis</source>. 
                    <year>2011</year>;
                    <volume>2011</volume>:
                    <fpage>536062</fpage>. 
                    <pub-id pub-id-type="doi">10.1155/2011/536062</pub-id>
                    <pub-id pub-id-type="pmid">22084665</pub-id>
                    <issn>2090-1488</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b25">
               <label>25. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Lim</surname>
                        <given-names>Y</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Lee</surname>
                        <given-names>EY</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Choi</surname>
                        <given-names>IS</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kim</surname>
                        <given-names>TY</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Yoon</surname>
                        <given-names>SS</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kim</surname>
                        <given-names>KH</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Leukopenia in patients with iron deficiency anemia</article-title>. 
                    <source>Blood</source>. 
                    <year>2011</year>;
                    <volume>118</volume>(
                    <issue>21</issue>):
                    <fpage>5279</fpage>.
                    <issn>0006-4971</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b26">
               <label>26. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Lima</surname>
                        <given-names>CS</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Paula</surname>
                        <given-names>EV</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Takahashi</surname>
                        <given-names>T</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Saad</surname>
                        <given-names>ST</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Lorand-Metze</surname>
                        <given-names>I</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Costa</surname>
                        <given-names>FF</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Causes of incidental neutropenia in adulthood</article-title>. 
                    <source>Ann Hematol</source>. 
                    <year>2006</year>
                    <month>Oct</month>;
                    <volume>85</volume>(
                    <issue>10</issue>):
                    <fpage>705</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s00277-006-0150-0</pub-id>
                    <pub-id pub-id-type="pmid">16807747</pub-id>
                    <issn>0939-5555</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b27">
               <label>27. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Lopas</surname>
                        <given-names>H</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Rabiner</surname>
                        <given-names>SF</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Thrombocytopenia associated with iron deficiency anemia. A report of five cases</article-title>. 
                    <source>Clin Pediatr (Phila)</source>. 
                    <year>1966</year>
                    <month>Oct</month>;
                    <volume>5</volume>(
                    <issue>10</issue>):
                    <fpage>609</fpage>–
                    <lpage>16</lpage>. 
                    <pub-id pub-id-type="doi">10.1177/000992286600501008</pub-id>
                    <pub-id pub-id-type="pmid">5926915</pub-id>
                    <issn>0009-9228</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b28">
               <label>28. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Morris</surname>
                        <given-names>VK</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Spraker</surname>
                        <given-names>HL</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Howard</surname>
                        <given-names>SC</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Ware</surname>
                        <given-names>RE</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Reiss</surname>
                        <given-names>UM</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Severe thrombocytopenia with iron deficiency anemia</article-title>. 
                    <source>Pediatr Hematol Oncol</source>. 
                    <year>2010</year>
                    <month>Aug</month>;
                    <volume>27</volume>(
                    <issue>5</issue>):
                    <fpage>413</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.3109/08880011003739455</pub-id>
                    <pub-id pub-id-type="pmid">20670168</pub-id>
                    <issn>0888-0018</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b29">
               <label>29. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Ganti</surname>
                        <given-names>AK</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Shonka</surname>
                        <given-names>NA</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Haire</surname>
                        <given-names>WD</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Pancytopenia due to iron deficiency worsened by iron infusion: a case report</article-title>. 
                    <source>J Med Case Reports</source>. 
                    <year>2007</year>
                    <month>Dec</month>;
                    <volume>1</volume>(
                    <issue>1</issue>):
                    <fpage>175</fpage>. 
                    <pub-id pub-id-type="doi">10.1186/1752-1947-1-175</pub-id>
                    <pub-id pub-id-type="pmid">18067664</pub-id>
                    <issn>1752-1947</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b30">
               <label>30. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Das Makheja</surname>
                        <given-names>K</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kumar Maheshwari</surname>
                        <given-names>B</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Arain</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kumar</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Kumari</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Vikash</surname>
                     </name>
                    </person-group>. 
                    <article-title>The common causes leading to pancytopenia in patients presenting to tertiary care hospital</article-title>. 
                    <source>Pak J Med Sci</source>. 
                    <year>2013</year>
                    <month>Sep</month>;
                    <volume>29</volume>(
                    <issue>5</issue>):
                    <fpage>1108</fpage>–
                    <lpage>11</lpage>.
                    <pub-id pub-id-type="pmid">24353701</pub-id>
                    <issn>1682-024X</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b31">
               <label>31. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Andrews</surname>
                        <given-names>NC</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Iron metabolism: iron deficiency and iron overload</article-title>. 
                    <source>Annu Rev Genomics Hum Genet</source>. 
                    <year>2000</year>;
                    <volume>1</volume>(
                    <issue>1</issue>):
                    <fpage>75</fpage>–
                    <lpage>98</lpage>. 
                    <pub-id pub-id-type="doi">10.1146/annurev.genom.1.1.75</pub-id>
                    <pub-id pub-id-type="pmid">11701625</pub-id>
                    <issn>1527-8204</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b32">
               <label>32. </label>
               <mixed-citation publication-type="book-chapter">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Andoljšek</surname>
                        <given-names>D</given-names>
                     </name>
                    </person-group>
                    <chapter-title>Bolezni krvi in krvotvornih organov</chapter-title>. In:
                    <person-group person-group-type="author">
                    <name name-style="western">
                        <surname>Kocijančič</surname>
                        <given-names>A</given-names>
                     </name>,
                     <name name-style="western">
                        <surname>Mrelje</surname>
                        <given-names>V</given-names>
                     </name>, 
                    <name name-style="western">
                        <surname>Štajer</surname>
                        <given-names>D</given-names>
                     </name>,
                        <name name-style="western">
                        <surname>černelč</surname>
                        <given-names>P</given-names>
                     </name>, 
                    <role>eds</role>
                    </person-group>. 
                    <source>Interna medicina</source>. 
                    <edition>3rd ed</edition>.
                    <publisher-loc>Ljubljana</publisher-loc>:
                    <publisher-name>Littera picta</publisher-name>;
                    <year>2011</year>.pp. 
                    <fpage>1243</fpage>–
                    <lpage>393</lpage>.
                </mixed-citation>
            </ref>
            <ref id="en-b33">
               <label>33. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Zijp</surname>
                        <given-names>IM</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Korver</surname>
                        <given-names>O</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Tijburg</surname>
                        <given-names>LB</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Effect of tea and other dietary factors on iron absorption</article-title>. 
                    <source>Crit Rev Food Sci Nutr</source>. 
                    <year>2000</year>
                    <month>Sep</month>;
                    <volume>40</volume>(
                    <issue>5</issue>):
                    <fpage>371</fpage>–
                    <lpage>98</lpage>. 
                    <pub-id pub-id-type="doi">10.1080/10408690091189194</pub-id>
                    <pub-id pub-id-type="pmid">11029010</pub-id>
                    <issn>1040-8398</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b34">
               <label>34. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Marignani</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Angeletti</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Bordi</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Malagnino</surname>
                        <given-names>F</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Mancino</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Delle Fave</surname>
                        <given-names>G</given-names>
                     </name>
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Reversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection</article-title>. 
                    <source>Scand J Gastroenterol</source>. 
                    <year>1997</year>
                    <month>Jun</month>;
                    <volume>32</volume>(
                    <issue>6</issue>):
                    <fpage>617</fpage>–
                    <lpage>22</lpage>. 
                    <pub-id pub-id-type="doi">10.3109/00365529709025109</pub-id>
                    <pub-id pub-id-type="pmid">9200297</pub-id>
                    <issn>0036-5521</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b35">
               <label>35. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Nairz</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Schroll</surname>
                        <given-names>A</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Sonnweber</surname>
                        <given-names>T</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Weiss</surname>
                        <given-names>G</given-names>
                     </name>
                    </person-group>. 
                    <article-title>The struggle for iron - a metal at the host-pathogen interface</article-title>. 
                    <source>Cell Microbiol</source>. 
                    <year>2010</year>
                    <month>Dec</month>;
                    <volume>12</volume>(
                    <issue>12</issue>):
                    <fpage>1691</fpage>–
                    <lpage>702</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1462-5822.2010.01529.x</pub-id>
                    <pub-id pub-id-type="pmid">20964797</pub-id>
                    <issn>1462-5814</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b36">
               <label>36. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Zager</surname>
                        <given-names>RA</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Johnson</surname>
                        <given-names>AC</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Hanson</surname>
                        <given-names>SY</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Parenteral iron therapy exacerbates experimental sepsis</article-title>. 
                    <source>Kidney Int</source>. 
                    <year>2004</year>
                    <month>Jun</month>;
                    <volume>65</volume>(
                    <issue>6</issue>):
                    <fpage>2108</fpage>–
                    <lpage>12</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1523-1755.2004.00742.x</pub-id>
                    <pub-id pub-id-type="pmid">15149323</pub-id>
                    <issn>0085-2538</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b37">
               <label>37. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Moretti</surname>
                        <given-names>D</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Goede</surname>
                        <given-names>JS</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Zeder</surname>
                        <given-names>C</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Jiskra</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Chatzinakou</surname>
                        <given-names>V</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Tjalsma</surname>
                        <given-names>H</given-names>
                     </name>
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women</article-title>. 
                    <source>Blood</source>. 
                    <year>2015</year>
                    <month>Oct</month>;
                    <volume>126</volume>(
                    <issue>17</issue>):
                    <fpage>1981</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1182/blood-2015-05-642223</pub-id>
                    <pub-id pub-id-type="pmid">26289639</pub-id>
                    <issn>0006-4971</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b38">
               <label>38. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Schrier</surname>
                        <given-names>SL</given-names>
                     </name>
                    </person-group>. 
                    <article-title>So you know how to treat iron deficiency anemia</article-title>. 
                    <source>Blood</source>. 
                    <year>2015</year>
                    <month>Oct</month>;
                    <volume>126</volume>(
                    <issue>17</issue>):
                    <fpage>1971</fpage>. 
                    <pub-id pub-id-type="doi">10.1182/blood-2015-09-666511</pub-id>
                    <pub-id pub-id-type="pmid">26494915</pub-id>
                    <issn>0006-4971</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b39">
               <label>39. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Bircher</surname>
                        <given-names>AJ</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Auerbach</surname>
                        <given-names>M</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Hypersensitivity from intravenous iron products</article-title>. 
                    <source>Immunol Allergy Clin North Am</source>. 
                    <year>2014</year>
                    <month>Aug</month>;
                    <volume>34</volume>(
                    <issue>3</issue>):
                    <fpage>707</fpage>–
                    <lpage>23</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.iac.2014.04.013</pub-id>
                    <pub-id pub-id-type="pmid">25017687</pub-id>
                    <issn>0889-8561</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b40">
               <label>40. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Rampton</surname>
                        <given-names>D</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Folkersen</surname>
                        <given-names>J</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Fishbane</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Hedenus</surname>
                        <given-names>M</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Howaldt</surname>
                        <given-names>S</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Locatelli</surname>
                        <given-names>F</given-names>
                     </name>
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management</article-title>. 
                    <source>Haematologica</source>. 
                    <year>2014</year>
                    <month>Nov</month>;
                    <volume>99</volume>(
                    <issue>11</issue>):
                    <fpage>1671</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.3324/haematol.2014.111492</pub-id>
                    <pub-id pub-id-type="pmid">25420283</pub-id>
                    <issn>0390-6078</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b41">
               <label>41. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Carson</surname>
                        <given-names>JL</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Strair</surname>
                        <given-names>R</given-names>
                     </name>
                    </person-group>. 
                    <article-title>Transfusion strategies in hematologic and nonhematologic disease</article-title>. 
                    <source>Hematology (Am Soc Hematol Educ Program)</source>. 
                    <year>2014</year>
                    <month>Dec</month>;
                    <volume>2014</volume>(
                    <issue>1</issue>):
                    <fpage>548</fpage>–
                    <lpage>52</lpage>. 
                    <pub-id pub-id-type="doi">10.1182/asheducation-2014.1.548</pub-id>
                    <pub-id pub-id-type="pmid">25696909</pub-id>
                    <issn>1520-4391</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b42">
               <label>42. </label>
               <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                        <surname>Goddard</surname>
                        <given-names>AF</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>James</surname>
                        <given-names>MW</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>McIntyre</surname>
                        <given-names>AS</given-names>
                     </name>, 
                        <name name-style="western">
                        <surname>Scott</surname>
                        <given-names>BB</given-names>
                     </name>; 
                        <collab>British Society of Gastroenterology</collab>
                    </person-group>. 
                    <article-title>Guidelines for the management of iron deficiency anaemia</article-title>. 
                    <source>Gut</source>. 
                    <year>2011</year>
                    <month>Oct</month>;
                    <volume>60</volume>(
                    <issue>10</issue>):
                    <fpage>1309</fpage>–
                    <lpage>16</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/gut.2010.228874</pub-id>
                    <pub-id pub-id-type="pmid">21561874</pub-id>
                    <issn>0017-5749</issn>
                </mixed-citation>
            </ref>
            <ref id="en-b43">
               <label>43. </label>
               <mixed-citation publication-type="webpage">
                    <source>Centralna baza zdravil 2</source>.
                    [<date-in-citation content-type="access-date" iso-8601-date="2017-01-11">cited 2017 Jan 11</date-in-citation>]. 
                    <comment>Available from:<uri>http://www.cbz.si/cbz/bazazdr2.nsf/Search?SearchView&amp;Query=(%5BSEZNAMUCINKNAZIV%5D=_%C5%BEelezo*)&amp;SearchOrder=4&amp;SearchMax=301</uri>
                  </comment>.
                </mixed-citation>
            </ref>
         </ref-list>
      </back>
   </sub-article>
</article>
